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Clinical research using herbal medicines requires specific considerations 
such as production method, which leads to chemical and pharmacological 
variability. Asthma is a leading chronic respiratory disease, remains sub-optimally 
controlled despite conventional costly treatments. Nigella sativa L. (NS) is a 
traditional herbal treatment for asthma, but lacking well-established scientific 
evidence. 
Objectives 
To develop an integrated research strategy incorporating preclinical and 
clinical research focusing on NS use in asthma by employing a chemically and 
pharmacologically well-characterised NS preparation in a well-designed clinical 
trial. 
Methods 
Distinct NS preparations were chemically characterised for thymoquinone 
(main active compound) concentration by High Performance Liquid 
Chromatography. Human T-lymphocyte, monocyte and A549 epithelial cells were 
utilised to assess the in-vitro anti-inflammation/immunomodulatory activity of NS 
preparations. The most potent and suitable NS preparation was clinically 
evaluated for efficacy as add-on treatment for asthmatics in a phase-II 
randomised double-blind placebo-controlled clinical trial (RDBPCT). Asthma 
Control Test (ACT) was the primary outcome. Pulmonary function, blood 
eosinophils and serum inflammatory markers were secondary outcomes. 
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Results and Discussion 
Ten different NS preparations were obtained, showing variability in 
thymoquinone concentration and in-vitro anti-inflammatory/immunomodulatory 
activities. Two thymoquinone-rich oily preparations (a super critical fluid extract 
and a commercial product registered in Saudi Arabia) showed the best in-vitro 
activity via inhibiting inflammatory cytokines in human cellular models. In the 
RDBPCT including 80 asthmatics, the commercial product capsules showed 
significant improvements in ACT, eosinophilia and some serum cytokines without 
serious side effects. 
Conclusion 
This project addressed important requirements to optimise clinical 
research using herbal medicines particularly for NS in asthma. Preclinical 
research on the chemistry and activity of the investigational NS product were the 
basis for the clinical trial. The RDBPCT revealed a higher level of evidence for 
the add-on NS treatment in asthma within the Saudi healthcare. This strategy is 
suggested for future clinical phytotherapeutic research. 
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INTRODUCTION: Review of the literature for Nigella sativa (NS) and 
its related activity in asthma inflammation. 
2 
EXTRACTION & PHYTOCHEMICAL ANALYSIS: The literature 
(Chapter 1) showed that NS used in various forms of preparations. 
Therefore, different types of NS preparations were obtained and 
chemically characterised (Chapter 2) 
3 
IN VITRO SCREENING: After the chemical characterisation of NS 
preparations (Chapter 2), various preclinical in vitro models were used 
to compare the anti-inflammatory/immunomodulatory activity of these 
preparations to find the most potent NS preparation (Chapter 3). 
4 
CLINICAL TRIAL: Based on the results of Chapter 2 & 3, the most 
suitable active NS preparation was selected for the clinical trial. A 
Phase-II randomised double-blind placebo-controlled clinical trial was 
conducted to explore the efficacy of the selected NS preparation in 
asthma (Chapter 4). 
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Research Impact Statement 
Phytotherapy is one of the common approaches of integrative medicine 
that is practised by different cultures based on traditional knowledge. In the era 
of evidence-based medicine, it is essential to investigate the specific clinical 
safety and efficacy information of herbal medicines based on scientific 
experimental and clinical approaches. In this project, we conducted a clinical trial 
in asthma using a chemically and pharmacologically characterised Nigella sativa 
(NS) preparation. The method used in this project could be employed as a 
resource guide for future research in the context of clinical trials with herbal 
medicines. The method comprised of specific criteria for selecting a suitable 
active extract with highlighting essential needs for conducting clinical trials on 
herbal medicines.  
Regarding outside academia benefits, this project provided an evidence-
based assessment of NS as a complementary treatment for asthma. This may 
have a positive impact on the quality of life and overall healthcare for patients 
with asthma by enhancing their disease control and minimising costs and side 
effects of the current conventional asthma medications.  
Also, this project highlighted some important quality characteristics of NS 
that could be used by herbal medicine industries and medicines agencies to 
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1 Chapter 1. Introduction* 
1.1 Introduction 
Asthma is considered as an epidemic respiratory disease probably affecting 
about 334 million people worldwide and becoming a global health priority (Global 
Asthma Network, 2014). In the United Kingdom, asthma affects one in every 
eleven people (Asthma UK, 2010). In Saudi Arabia (with a population of 28 
million), the prevalence of asthma is increasing and affects more than 2 million 
Saudis (Al-Moamary, 2012).  
Patients with asthma may tend to use complementary and alternative 
therapies such as herbal medicines as a holistic approach to asthma 
management due to limitations of conventional asthma medications (Kohn and 
Paudyal, 2017). In Saudi Arabia, a survey of two hundred patients with asthma 
found that 34.5% used unconventional therapies for asthma. For example, the 
seeds of the medicinal plant Nigella sativa L. (NS) was one of the most common 
such therapies (Al Moamary, 2008). However, these therapies often have 
insufficient evidence for its clinical use in asthma (Kohn and Paudyal, 2017). 
Therefore, this project explored and assessed the current scientific evidence for 
the use of NS in asthma, followed by conducting a high-quality clinical trial for 
investigating the clinical efficacy of NS in patients with asthma. 
In this chapter, asthma disease and management were introduced. Also, 
the traditional medical applications, safety and chemical composition of NS were 
reviewed as well as the evidence of NS use in asthma was assessed.  
*Part of the information in this chapter is published; 
Koshak, A., Koshak, E. and Heinrich, M. (2017) ‘Medicinal benefits of Nigella 
sativa in bronchial asthma: A literature review’, Saudi Pharmaceutical Journal. 
doi: 10.1016/j.jsps.2017.07.002. 
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1.2 Asthma definition and pathophysiology 
The Global Initiative for Asthma (GINA) guidelines 2017 defined asthma as 
“a heterogeneous disease, usually characterised by chronic airway inflammation 
which is identified by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in 
intensity, together with variable expiratory airflow limitation”. Usually, it is 
accompanied by lung hyper-responsiveness and inflammation. It is often induced 
by certain factors such as exercise, allergen or irritant exposure, weather 
variation, or viral infection (Global Initiative for Asthma, 2017).  
Asthma is initiated by multiple interactions between inflammatory cells and 
mediators. The most important cells involved in asthma inflammation are mast 
cells, eosinophils, T lymphocytes, neutrophils, and epithelial cells. After exposure 
to a triggering factor, inflammatory mediators are released from mast cells, 
macrophages, T-lymphocyte cells and epithelial cells. This causes attraction of 
other inflammatory cells mainly eosinophils into the pulmonary tissues which 
produce chemical compounds such as major basic protein (MBP) and eosinophil 
cationic protein (ECP). This leads to lung injury, mucus hypersecretion and 
smooth muscle hyperactivity. In fact, there are at least 27 cytokines and 18 
chemokines that play a role in asthma pathophysiology (Koda-Kimble, 2009). 
Type 2 T helper (Th2) cells cytokines [interleukin IL-4, IL-5, and IL-13] and 
Type 1 T helper (Th1) cells cytokine interferon-gamma are considered to be the 
main cytokines in asthma (Ngoc et al., 2005). Although Th2-related eosinophilia 
is considered to be the classical pathway of inflammation in asthma, Th17-related 
neutrophilia have been associated with more severe type steroid-resistant 
asthma (Figure 1) (Trevor and Deshane 2014).  
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Asthma is classified according to demographic, clinical and 
pathophysiological characteristics which referred as asthma phenotypes. These 
phenotypes of asthma include allergic asthma, non-allergic asthma, late-onset 
asthma, asthma with fixed airflow limitation and asthma with obesity. Allergic 
asthma is the most easily recognised phenotype that is associated with 
eosinophilic airway inflammation.  The cellular inflammatory profile of non-allergic 
asthma may be neutrophilic, eosinophilic or contain only a few other inflammatory 
cells (Global Initiative for Asthma, 2017). 
Figure 1. Type 2 T helper cells and Type 17 T helper cells mediated inflammatory 
pathway in asthma (Trevor and Deshane, 2014). 
 
1.3 Asthma management and assessment of disease control 
The key goals for asthma management are to achieve a good control of 
symptoms and minimise the future risk of exacerbations, airflow limitation and 
treatment adverse events. Assessment of asthma control level is done by 
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evaluating the frequency of asthma symptoms (days per week), limitation of 
activity or night waking due to asthma, and the frequency of reliever medications 
use. This can be done by using several tools including simple, categorical or 
numerical tools. Numerical tools provide scores that can be used to assess the 
progress of control and commonly used in clinical trials. For example, Asthma 
Control Test (ACT) is a validated numerical tool to assess asthma control 
characterised by a score range from 5 to 25 (high number means better control). 
On the other hand, future risk can be assessed by pulmonary function testing, 
particularly the forced expiratory volume in 1 second (FEV1) (Global Initiative for 
Asthma, 2017).  
Asthma control is achieved by both non-pharmacological and 
pharmacological therapies. Medications for asthma are categorised into three 
main classes. First, controller medications to decrease lung inflammation, 
future risks and increase control of symptoms. This includes inhaled 
corticosteroids, leukotriene receptor antagonists and long-acting β2-agonist. 
Second, reliever medications which are used when required for relief and 
prevent emergent symptoms such as short-acting β2-agonist. Third, add-on 
therapies for severe asthma that is difficult to control such as anti-IgE (Global 
Initiative for Asthma, 2017). 
Traditionally, the strategy for asthma therapy focused on bronchodilation 
and decreasing airway inflammation. This can be achieved by inhaled 
medications. However, inhaled medications have shortcomings such as poor 
penetration into the peripheral airways and inadequately treat the systemic 
component of asthma. Oral systemic therapies can reach the small airways and 
treat the systemic component of asthma (Bjermer, 2001, 2007).  
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Therefore, the current and future research trend of asthma management is 
focusing on phenotype-guided add-on systemic medications, through targeting 
disease-specific inflammatory mediators and biomarkers such as anti-IL5 (Global 
Initiative for Asthma, 2017; Pavord et al., 2017). 
1.4 Asthma control and limitations of asthma medications 
Currently, asthma control is considered to be suboptimal regardless of the 
availability of conventional treatments (Demoly et al., 2012; Price, Fletcher and 
van der Molen, 2014). Data from the Recognise Asthma and Link to Symptoms 
and Experience (REALISE) survey in 2014 for 8000 European patients 
revealed that the level of asthma control remains low (Price, Fletcher and van 
der Molen, 2014). 
One of the reasons for low asthma control is poor adherence to asthma 
medications (Horne et al., 2007; Haughney et al., 2008). Common medication-
related reasons for non-adherence include difficulties with inhaler techniques, the 
complex course of therapy, adverse events, and cost of medications (Bateman 
et al., 2008; Dima et al., 2015).  
The Global Asthma Physician and Patient (GAPP) Survey reported that 
39% of asthma patients exchanged or stopped their asthma medication due to 
adverse events (GAPP, 2005). 76% of patients and 81% of physicians consider 
that new treatment options are required (GAPP, 2005).  
1.5 Phytotherapy in Asthma 
In general, asthma patients may tend to use complementary and alternative 
therapies such as herbal medicines as a holistic approach to disease 
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management due to limitations of asthma medications (Kohn and Paudyal, 2017). 
The introduction of novel treatment strategies such as “add-on” treatments is 
recommended for better asthma control (Lommatzsch and Stoll, 2016). Herbal 
medicine may be considered as a possible add-on treatment option. For example, 
butterbur (Petasites hybridus L.) was studied as add-on therapy in a small 
randomised double-blind placebo-controlled study included 16 asthmatic 
patients. It improved asthma outcomes including FEV1, exhaled nitric oxide, 
serum eosinophil cationic protein and peripheral blood eosinophil count (Lee et 
al., 2004). 
Several herbal medicines were reported in clinical trials of asthma such as: 
Nigella sativa L. (NS), Ginkgo biloba L., Ligusticum wallichii Franch., Ephedra 
sinica Stapf., Solanum xanthocarpum L., Solanum trilobatum L., Boswellia 
serrata Roxb., Tylophora indica Merr., Cannabis sativa L., Hedera helix L., 
Petasites hybridus L., Eucalyptus oil, Sophora flavescens Aiton, Glycyrrhiza 
uralensis Fisch., and Aleurites moluccanus L. However, the clinical efficacy and 
safety evidence for these herbal medicines is limited and there is a need for 
further proper investigations in randomised controlled trials to evaluate the use of 
herbal medicines in asthma (Huntley and Ernst, 2000; Slader et al., 2006; Singh 
et al., 2007; Clarke, Lundy and McGarvey, 2015; Kohn and Paudyal, 2017). 
Therefore, phytotherapy remains a commonly used but poorly investigated 
element in asthma management. 
In Saudi Arabia, a questionnaire for 69 patients with asthma found that NS 
was the most frequently used herb as a non-standard treatment. This was 
followed by Myrrh (Commiphora myrrha (Nees)), Garlic (Allium sativum L.), Gum 
(not specified) and Fenugreek (Trigonella foenum-graecum L.) (Al Moamary, 
2008). 
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1.6 Clinical research in phytotherapy 
Clinical trials are essential to establish the scientific evidence base use of 
herbal medicines. Systematic reviews and meta-analysis of randomised 
controlled trials are considered the highest level of evidence (Edwards et al., 
2012). Compared to conventional medicines, few herbal medicines were 
investigated in a good quality clinical trials (Willcox, 2014). For example, St John’s 
wort (Hypericum perforatum L.) was found to be equivalent to selective serotonin 
uptake inhibitors in managing patients with major depression according to a 
review of 29 randomised double-blind controlled trials (Edwards et al., 2012). 
Therefore, there is a need for high-quality clinical research for many other herbal 
medicines. 
Due to the nature of herbal medicines, factors such as the chemical 
composition and plant part used should be considered before commencing to 
well-designed clinical trials (Edwards et al., 2012). Challenges of clinical trials in 
phytotherapy include herbal product standardisation (or characterisation) as well 
as financial, ethical, regulatory, and trial design factors (Parveen et al., 2015). 
One of the approaches for overcoming the high cost of clinical trials is by 
collaborating with regional research institutes and with doctoral students, 
focusing mainly on validated clinical outcomes rather than expensive laboratory 
analyses (Graz, Elisabetsky and Falquet, 2007). 
1.7 Pre-clinical models of pulmonary inflammation 
Pulmonary inflammation is a base for several respiratory diseases such as 
asthma, chronic obstructive pulmonary disease (COPD), and acute respiratory 
distress syndrome (ARDS). These diseases are most commonly managed by 
anti-inflammatory treatments to reduce the pulmonary inflammation. 
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Inflammation is a cellular response that can occur in the lung by the induction of 
external or internal factors. While it is considered a normal response in the human 
body, chronic inflammation could damage the lung. Pulmonary inflammation 
involves many inflammatory cells, such as macrophages, lymphocytes, 
neutrophils, and eosinophils. Also, the epithelium, smooth muscle, and vascular 
and neuronal elements are involved in the pathogenesis of pulmonary 
inflammation. In general, these cells release inflammatory mediators such as 
histamine, tumour necrosis factor (TNF-α), interleukins (IL-1β, IL-4, IL-5, and IL-
6), prostaglandins, leukotrienes, and nitric oxide. These inflammatory mediators 
are related to the signals and symptoms of pulmonary diseases such as airway 
hyperresponsiveness and obstruction, airway oedema, mucus hypersecretion, 
and lung remodelling (Barnes, 2000; Ware and Matthay, 2000; Murphy and 
O’Byrne, 2017). 
Several animal models were used in the drug discovery for pulmonary 
disease. For example, histamine and acetylcholine induced bronchoconstriction 
in Guinea pigs, Egg Albumin Sensitized Guinea Pigs and its effects on Broncho 
Alveolar Lavage Fluid (BALF), Clonidine-induced Catalepsy in Mice, Clonidine-
induced Mast Cell Degranulation in Rats, Milk-Induced Leucocytosis and 
Eosinophilia in Mice were used as in vivo animal models in asthma disease. In 
vitro models involving part of an animal were also used in models for asthma such 
as vascular and airway responses in isolated perfused rat lung preparation, and 
the contractions induced by histamine, acetylcholine, serotonin and bradykinin in 
isolated goat tracheal chain preparation or guinea pig ileum (Patil and Ninave, 
2016). However, animal models may explore only a part of many pathways in 
human disease and have the species specific limitations which need to be 
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considered when translating results from animal models into human (Holmes, 
Solari and Holgate, 2011). 
In comparison to animal in vivo models, in vitro studies offer several 
advantages as it may be more easy, flexible, quick, economical and reproducible. 
Also, it can reduce the number of animals used in research, avoid animal species 
variation and provide direct access to investigate cellular components and 
biomolecules (Adamson et al., 2011).   
Human tissue-based ex vivo and in vitro asthma models can be used in 
pulmonary inflammation research. They can be ranged from little structural 
organisation to complex 3-D cultures containing different cell types that are 
organised into a human structure that retains (ex vivo tissue explants) or mimics 
(tissue engineered in vitro models) some human characteristics. Cultured tissue 
from resected human lung is an example of an ex vivo model. However, it is 
limited by the relatively short-term viability and the barrier properties of the 
epithelial layer.  
Cell lines and primary human cells derived from pulmonary tissue are the 
simplest human based models. It is commonly used for investigating basic 
cellular responses and cell signalling pathways of the lung. For example, the 
A549 bronchial epithelial cell line is being used for lung diseases research. They 
are readily accessible and easy to manipulate but they don’t explore the genetic 
or epigenetic features of the disease. Another example is the in vitro cultured 
primary human cells such as bronchial epithelial cells from bronchial brushings 
or biopsies, fibroblasts and smooth muscle cells from bronchial biopsies, and 
immune cells from bronchoalveolar lavage or peripheral blood. These cell types 
may reflect genetic or epigenetic changes but a special technique such as 
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bronchoscopy that may limit obtaining a bronchial biopsy for example. A major 
limitation of such models is that they investigate responses only from a single 
isolated cell type. Therefore, co-culture models and 3D tissue were manipulated 
to include more than one type of cell and extracellular matrix components leading 
to an attempt to mimic the in vivo environment. However, such models may be 
more complex to grow as it needs optimisation of media compatibility for different 
types of cells (Blume and Davies, 2013). 
1.8 Nigella sativa L. 
The seeds of the medicinal plant Nigella sativa L. (NS) are commonly used 
as a spice known as black cumin seeds. It has traditional medical applications 
and considered to be a characteristic traditional herbal medicine for diverse 
diseases in the Unani, Arabic, Prophetic and Indian traditional medicines (Ahmad 
et al., 2013). Popular ancient physicians such as Hippocrates (460-370 BC), 
Dioscorides (40-90 AD), Galen (130-210 AD), and Avicenna (980-1037 AD) 
reported various traditional therapeutic uses of NS (Botnick et al., 2012). In the 
Islamic literature, it was metaphorically regarded as a cure for all diseases except 
death (Muhammad al-Bukhari, 854). It is recognised as the curative black cumin 
in the Bible and mentioned in the Hebrew word “ketzah” in the book of Isaiah 
(28:27) (Duke, Duke and DuCellier, 2008). 
The plant is native to North Africa, Southern Europe, and Southwest Asia. 
However, it is cultivated in many countries such as India, Pakistan, Syria, Turkey, 
Saudi Arabia and other Middle Eastern, Mediterranean and South European 
countries (Khare, 2004). It has several non-scientific names in different 
languages including common names in English such as black cumin, black seed, 
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black caraway, fennel flower, nutmeg flower, or Roman coriander. Nigella sativa 
was first described by Carl Linnaeus (L.); 1707-1778 (Kew, 2017). 
1.9 Traditional medical uses of Nigella sativa 
For hundreds of years, NS was an important natural remedy for many 
diseases. Popular ancient physicians reported its various therapeutic uses in 
traditional medicine. For instance, Avicenna reported its benefit for shortness of 
breath (سفنلا باصتنا) and for stopping phlegm (مغلبلا عطقم) (Avicenna, 1593). 
Dioscorides reported its medical use for cleaning rough skin and psoriasis 
(Osbaldeston, 2000). Moreover, Hippocrates used it for treating hepatic and 
digestive conditions (Salama, 2010). The Muslim scholar Imam Ibn Qayyim Al-
Jawziyya (1292–1350 AD), the author of the Prophetic Medicine, reported that 
NS alleviate gasping and hard breathing (Abdullah, 2003). 
 In Arabia, NS is a traditional remedy for asthma, cough, stomach ache, 
abdominal pain, colic, general fatigue, rheumatism, and skin diseases. Also, it is 
thought to be good for stimulating digestive, kidney and brain functions. It is 
traditionally believed to strengthen women after giving birth, stimulate 
menstruation and support beauty treatments for hair and skin (Lebling and 
Pepperdine, 2006). In Saudi Arabia, NS was a common non-standard treatment 
used by patients with asthma (Al Moamary, 2008). 
1.10  Chemical composition of Nigella sativa 
The chemical composition of NS has been studied in considerable detail in 
several studies. Mainly, it contains fixed oil (24.76 to 40.35%), volatile oil (0.5 to 
1.6%), alkaloids, saponins, and other compounds in trace amounts (Table 1) 
(Ahmad et al., 2013; Botnick et al., 2012; Liu et al., 2011).  Because these 
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compounds have different hydrophilic/hydrophobic properties, the extraction 
method influences the chemical composition and, consequently, the 
pharmacological activity of an NS preparation. Therefore, we investigated the 
pharmacological activity of different NS preparations to select a suitable active 
preparation of NS as explained in chapter 3. 
The compounds responsible for NS’s activities are still not well-established. 
It is likely that several compounds are responsible or co-responsible for NS 
activity and that one must consider a specific extract as the active ingredient 
rather than a single compound. Thymoquinone (TQ) (Figure 2) is the main 
component of NS’s volatile oil that is considered to be an active compound in 
several studies (Ahmad et al., 2013). TQ was first isolated from NS oil in 1963 
(El–Dakhakhny, 1963). TQ has very low stability profile in aqueous solutions 
(Salmani et al., 2014). Other compounds such as dithymoquinone, 
thymohydroquinone, thymol, carvacrol and α-hederin were also reported to 
produce relevant pharmacological effects in preclinical models (Marsik et al., 
2005; Landa et al., 2009; Fallahi et al., 2016).  
Table 1. Identified metabolites in Nigella sativa. 
Class Compounds 
Alkaloids 
- Dolabellane-type diterpene alkaloids: Nigellamines A1, 
A2, A3, A4, A5, B1, B2 and C. 
- Indazole alkaloids: Nigellidine, nigellicine and nigellidine-
4-O-sulfite. 




- Diacylglycerols, fat-soluble vitamins, lipases, 
monoacylglycerols, phospholipids, triacylglycerols. 




- Saturated fatty acids: Arachidic, behenic, lauric, 
lignoceric, smyristic, palmitic and stearic acid. 
- Sterols: Campestrol, cholesterol, stigmasterol, β-sitostanol, 
β-sitosterol,  Δ5-avenasterol, Δ7-avenasterol, Δ7-
stigmasterol and lophenol. 
- Unsaturated fatty acids: Dihomolinoleic, eicosadienoic, 
erucic, linoleic (52.6% - 55.6%), linolenic, margaroleic, oleic 
(23.4% - 23.5%) and palmitoleic acids.  
Saponins - α-hederin and hederagenin. 
Volatile oils 
(0.5–1.6%) 
- Aldehydes: 2E,4Z-decadienal, 2E,4E-decadienal. 
- Monoterpene alcohols: Carvacrol, terpinene-4-ol and 
thymohydroquinone. 
- Monoterpene ester: bornyl acetate. 
- Monoterpene ethers: cis-4-methoxythujane, trans-4-
methoxythujane, 4,5-epoxy-1-isopropyl-4-methyl-1-
cyclohexene. 
- Monoterpene hydrocarbons: Limonene, myrcene, p-
cymene, sabinene, terpinolene, α-pinene, α-terpinene, α-
thujene, β-pinene and γ-terpinene. 
- Monoterpene ketones: Carvone, thymoquinone and 
nigellone. 
- Sesquiterpenes: Longifolene, longipinene, trans-
caryophyllene and zonarene. 
Other Vitamins, minerals, proteins, resins and tannins. 
Figure 2. The chemical structure of thymoquinone (PubChem database).
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1.11 Safety of Nigella sativa 
Generally, NS considered a food substance, and for centuries has been 
used by many communities. The toxicity of NS has been investigated in various 
animal and clinical studies. The acute and chronic toxicity of NS oil was studied 
as shown in the following animals.  In mice, the administration of 28.8 ml/kg oral 
and 2.06 ml/kg intraperitoneal single doses of NS oil resulted in high lethal doses 
(LD50) of 28.8±1 ml/kg for oral, and 2.06 ± 0,1 ml/kg for intraperitoneal doses. In 
rats, oral dose of 2 ml/kg for 12 weeks showed no changes in the levels of liver 
enzymes or the histopathology of the heart, liver, kidneys and pancreas as well 
as decreased serum levels of cholesterol, triglycerides and glucose (Zaoui et al., 
2002). 
Additionally, the acute and subacute toxicity of the aqueous, methanol and 
chloroform extracts of NS were shown to be low (Vahdati-Mashhadian, 
Rakhshandeh and Omidi, 2005). After oral administration of four different single 
doses of each extract (6, 9, 14 and 21 g/kg) in mice, no mortality occurred with 
all doses. Also, prolonged administration of these extracts for 14 days showed no 
significant effects on weight, plasma levels of liver enzymes and overall health 
(Vahdati-Mashhadian, Rakhshandeh and Omidi, 2005).  
Powdered NS in the dose of up to 1 g/kg/day for 28 days had no changes 
in liver enzymes level and did not cause any toxic effects on the liver function in 
rats (Dollah et al., 2013). A dose of 2g/day for 6 weeks of powdered NS did not 
show any adverse effects on liver or kidney function tests in a clinical trial 
including 64 patients (Qidwai et al., 2009). Furthermore, high doses of powdered 
NS (3g/day) did not show any toxic effects in clinical trials (Bamosa, 2014). The 
relative safety of the major active compound TQ was evident due to high LD50 
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values which were 870.9 mg/kg (647.1–1094.8) for oral and 104.7 mg/kg (89.7–
119.7) for intraperitoneal administration of TQ in experimental animals (Al-Ali et 
al., 2008). 
1.12  Pharmacokinetics of thymoquinone 
The clinical bioavailability and pharmacokinetic parameters for 
thymoquinone are not well established (AbuKhader, 2013). However, in an 
animal rabbit study, the oral bioavailability of 20 mg/kg of TQ was about 58% with 
slow absorption (T ½ 217 min) and rapid elimination (T ½ 274.61 ± 8.48 min) 
(Alkharfy et al., 2015).  
1.13 Evidence for Nigella sativa’s efficacy in asthma 
Between the years 1990 and 2016, a literature search for scientific studies 
published in electronic databases (PubMed, Science Direct, Scopus, and Google 
Scholar) was done using the terms Nigella sativa, black seed, thymoquinone and 
asthma. At least nineteen pre-clinical studies and six clinical studies reported 
the effects of NS in asthma. 
1.13.1 Pre-clinical studies of Nigella sativa in cellular and animal 
models of asthma 
NS and its active compounds TQ, nigellone and α-hederin have been 
investigated in eighteen whole or cellular animal models and one human cellular 
model related to asthma. NS oil, TQ or α-hederin showed anti-inflammatory and 
immunomodulatory effects in seven studies (Mansour and Tornhamre, 2004; 
Abbas et al., 2005; El Gazzar et al., 2006; Shahzad et al., 2009; Balaha et al., 
2012; Saleh, ElDenshary and Mahran, 2012; Saadat et al., 2015). NS extracts, 
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TQ or α-hederin demonstrated a bronchodilatory or relaxant effect in six studies 
(Al-Majed et al., 2001; Gilani et al., 2001; Boskabady, Keyhanmanesh and 
Saadatloo, 2008; Abd El Aziz, El Sayed and Mahran, 2011; Keyhanmanesh et 
al., 2013; Saadat et al., 2015). The anti-histaminic effect was shown in four 
studies used NS oil/aqueous extract, nigellone or α-hederin (Chakravarty, 1993; 
Abd El Aziz, El Sayed and Mahran, 2011; Saleh, ElDenshary and Mahran, 2012; 
Saadat et al., 2015). Pathological improvements were shown using TQ or NS oil 
in five studies (Boskabady and Sheiravi, 2002; El Gazzar et al., 2006; Shahzad 
et al., 2009; Kalemci et al., 2013; Arabzadeh, Mirdar and Moradiani, 2016). The 
summary of findings of these studies is shown in Table 2. 
Generally, these studies used animal models sensitised with ovalbumin or 
isolated guinea pig trachea. Some studies used cellular models such as human 
granulocytes or animal mast cells. However, these studies had limitations such 
as the variability of NS preparations used between most them, and absence of 
control group in some studies (Table 2). 
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(Chakravarty, 1993) Nigellone 11µg/ml 
in vitro 




N/A N/A    ↓    No control 
group 
(without TQ) 









histamine or K+ 
N/A N/A      +  No control 
group 
(without TQ) 
(Al-Majed et al., 
2001) 












0.3ml in vitro Guinea pig 
trachea induced 
by histamine 
Saline CHL     +    
(Mansour and 
Tornhamre, 2004) 










N/A  ↓ leukotrienes      No positive 
control 





Untreated mice DEX ↓ IgG ↓ serum IL-2 & IL-
12 
↓ eosinophils in 
blood 
     
(Büyüköztürk et al., 
2005) 




Saline   No change in IL-4, 
IL-10 and IFN- γ in 
splenic 
mononuclear cells 
     No positive 
control 
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(El Gazzar et al., 
2006) 
TQ + 10% 
DMSO 
3 mg/kg TQ in 10% 
DMSO ip for 5 
days 
OVA sensitised 
BALB/c mice and 
lung cells 









↓ IL-4, IL-5, IL-13 
↑ IFN-γ 
in BALF 
↓ eosinophils in the 
lung & BALF 








-0.8 g% of 
methanol extract 







THEO      +   
(Shahzad et al., 
2009) 












expression of IL-4, 
IL-5, IL-6 and 
TGF-β1 from lung 
cells 




lymphocytes in the 
lung & BALF 
 
   ↓ bronchial and alveolar 
epithelial hyperplasia 




(Abd El Aziz, El 
Sayed and Mahran, 
2011) 
TQ -3 mg/kg ip for 5 
days in guinea pig 
-8 mg/kg ip for 21 










N/A    ↓  +  No positive 
control 
(Balaha et al., 2012) NS fixed oil Oral NS oil 4 









↑ BALF Th1 
cytokines 











and Mahran, 2012) 
NS fixed oil Oral NS oil 2.5 









Saline N/A  ↑ PGE2 in lung 
tissue 
↓ leukotrienes 














THEO      +   
(Kalemci et al., 
2013) 




Saline DEX       ↓ Sub-epithelial and 
epithelial hyperplasia 
↓ Number of mast and 
goblet cells 
 




TQ 0.3 mg/kg ip OVA sensitized 
guinea pig 
Saline N/A  ↑ Blood IFN-γ ↓ Eosinophil 
↓ Basophils in 
BALF 
   ↓ Tracheal responsiveness 
↓ Airway membrane 
hyperplasia 
↓ Respiratory epithelial 
denudation 




(Saadat et al., 2015) α-hederin 0.3 mg/kg ip OVA sensitized 
guinea pig 
Saline TQ   ↓ Total WBC 
↓ Eosinophils 
↓ Basophils in 
BALF 
  + ↓ Tracheal contractile 
response to histamine 
 
(Fallahi et al., 2016) α-hederin 0.2 mg/kg ip OVA sensitized 
Wistar rats 
Saline TQ  ↓ IL-13 mRNA 
↓ miRNA-126 
    ↓ Pneumocyte and 



















rats without NS 
N/A       ↓ thickness of epithelial 
bronchi, tunica media 
(muscle) bronchi, and tunica 
adventitia bronchi 
↓ number of goblet cells 
No positive 
control 
Ip; intraperitoneal. OVA; ovalbumin. BALF; Bronchoalveolar lavage fluid. N/A; data not included in the original study. TQ; Thymoquinone. DEX; Dexamethasone. CHL; Chlorpheniramine. THEO; Theophylline. 
A23187; Calcium Ionophore to investigate LTC4 and LTB4 formation. LTA4; Leukotriene A4 to investigate LTA4 hydrolase and LTC4 synthase activity by the formation of LTC4 and LTB4 formation. AA; 
Arachidonic Acid to investigate 5-lipoxygenase activity by formation of 5-Hydroxyicosatetraenoic acid. 
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1.13.2 Clinical studies of Nigella sativa in patients with asthma 
Six clinical studies showed a potential efficacy of NS on asthma outcomes 
and biomarkers. Two Randomised Double-Blinded Placebo-Controlled Clinical 
Trials (RDBPCT) and Two Randomised Single-Blinded Placebo-Controlled 
Clinical Trials (RSBPCT) using NS crushed seeds powder or oil/aqueous extract, 
showed an improvement in clinical symptoms and pulmonary function test in adult 
asthmatics (Kalus et al., 2003; Boskabady et al., 2007; Kardani et al., 2013; 
Salem et al., 2017). A nonsignificant reduction of blood eosinophilia and total 
serum IgE was found within the treatment group only in an RDBPCT (Kalus et 
al., 2003). A significant reduction of fractional exhaled nitric oxide and increase 
of serum interferon gamma were found in a RSBPCT (Salem et al., 2017). A 
Randomised Double-Blinded Clinical Trial (RDBCT) showed a short 
bronchodilatory effect in patients with asthma after administration of a single dose 
of NS (Boskabady, Mohsenpoor and Takaloo, 2010). Two studies used NS in 
combination with other treatments showed an improvement in either clinical 
symptoms or pulmonary function (Al Ameen et al., 2011; Kardani et al., 2013) 
(Table 3).  
However, these clinical trials had some important limitations as mentioned 
in Table 3. The quality of trials was not high as two studies only were RDBPCT. 
There was a variability in the NS preparation type between the trials and the 
phytochemical characterisation of the investigational NS product was not shown 
in many of these trials. In most studies, the sample size was comparatively small 
and the outcomes were generally limited to symptoms or pulmonary function. A 
meta-analysis is suggested for these clinical trials. However, due to the variability 
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of outcomes measured between trials and limited sample size, it was not suitable 
to perform a meta-analysis for the outcomes of these trials.  
Therefore, there is a need for a longer, larger and high quality multicentre 
clinical trial with chemically well-characterised NS product. Also, to use validated 
asthma control measurement tool with consideration of additional asthma 
outcomes and biomarkers such as FeNO, Sputum eosinophils, total blood 
eosinophils, total serum Immunoglobulin E (IgE), allergen-specific IgE and 
urinary leukotriene E4 LTE4 (Szefler et al., 2012). Additionally, measuring serum 
inflammatory cytokines may be worth considering, since asthma is regulated by 
multiple inflammatory cytokines and asthma control might be predicted with some 
cytokines. For example, high serum level of the anti-inflammatory cytokine 
Interleukin-10 (IL-10) was associated with reduced risks of deteriorating asthma 
control, asthma attacks and low IgE levels (Akiki et al., 2017). 
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3 weeks 63 allergic adults: 
- 31 allergic rhinitis 
- 3 bronchial asthma  





 ↓ eosinophils 
(not 
significant)  
↓ serum IgE 
(not 
significant) 
- Sample of mixed allergic patients 
- No pulmonary function measurement 
- Blood biomarkers were not compared 
between groups 
- limited NS characterisation 
- invalidated symptoms scoring system 
(Boskabady 




RDBPCT Placebo 15 
mL/kg of 
0.1 g%  











 + NS was chemically characterised 
+ High standard study design 
- Small sample size 
- Limited outcomes to symptoms and 
pulmonary function 












150 min 15 adult asthmatics 
 




 + NS was chemically characterised 
- Very small sample size 
- Not placebo controlled 
+ limited outcomes to pulmonary function 





Non RCT  
open-label 




3 months 5 adult asthmatics  
 
 ↑ FVC in 
asthmatics 
 
 - Very small sample size 
- NS was not chemically characterised and 
was used in combination 
- Low standard study design 
- Outcomes were limited and statistically 
compared within the same group only, and 
not between groups.  












15 mg / 
kg / day  
14 weeks 31 child asthmatics 
G1: 8 IM + placebo 
G2: 8 IM + NS  
G3: 8 IM + probiotic 
G4: 7 IM + NS + probiotic 
↑ ACT  No change in 
Th17 cells 
- Small sample size 
+ NS not chemically characterised and 
was used in combination 
- Single-blinded 
- Outcomes limited to symptoms only 




RSBPCT Placebo 1 & 2 
g/day 
3 months 76 adult asthmatics 
-24 placebo 
-26 (1 g NS) 
-26 (2 g NS) 




↓ serum IgE 
↑ serum IFNγ 
↓ FeNO 
+ Large sample size but still 
comparatively small 
+ Longer duration 
- Single-Blinded 
- NS was not chemically characterised 
RDBPCT; Randomised Double-Blind Placebo-Controlled Trial. RSBPCT; Randomised Single-Blind Placebo-Controlled Trial. RDBCT: Randomised Double-Blind Controlled Trial. ACT; Asthma control test. 
FEV1; forced expiratory volume in 1 second. FVC; forced vital capacity. MMEF; maximal mid expiratory flow. PEF; peak expiratory flow. Tsp; tea spoonful. FeNO; fractional exhaled nitric oxide. FEF25-75%; 
mid expiratory flow. IM; Immunotherapy. THEO; Theophylline. G; Group. 
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Table 3.1 Asthma symptoms outcomes in the clinical studies of Nigella sativa in patients with asthma. 
Study reference Asthma symptoms 
(Boskabady et al., 2007)  
 Baseline Post-treatment 
 Control (Placebo) Study p Control (Placebo) Study p 
Asthma severity score 3.20 ± 0.19 3.27 ± 0.18  Not significant 5.36 ± 3.87 49.45 ± 3.50 < 0.001 
Data are presented as mean ± SEM 
 
(Kardani et al., 2013)  
 Control (IM + Placebo) Treatment (IM + NS) 
 Baseline Post-treatment p Baseline Post-treatment p 
Asthma Control Test 15.86 (5.15) 18.00 (7.42) 0.062 16.00 (2.73) 20.75 (3.37) 0.001 
Data are presented as mean (SD) 
 
(Salem et al., 2017)  
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Table 3.2 Pulmonary function outcomes in the clinical studies of Nigella sativa in patients with asthma. 
Study reference Pulmonary function 
(Boskabady et al., 2007)  
 Baseline End of treatment 
 Control (Placebo) Study  p Control (Placebo)  Study  p 
FEV1 52.1 ± 4.50 58.8 ± 5.00 Not significant 3.30 ± 6.50 29.47 ± 5.04 < 0.005 
PEF 38.8 ± 3.70 53 ± 5.21 < 0.05 -0.66 ± 7.20 31.18 ± 3.80 < 0.001 
Data are presented as mean ± SEM 
 
(Boskabady, Mohsenpoor and Takaloo, 2010)  
 Control (Theophylline) Treatment 
 Baseline Post-treatment p Baseline Post-treatment p 
FEV1 2.32 ± 0.35 ↑ by 8.58 ± 1.43 % < 0.01 2.14 ± 0.21 ↑ 3.85 ± 0.54 % < 0.001 
PEF 3.46 ± 0.55 ↑ by 6.15 ± 1.51 % Not significant 3.18 ± 0.39 ↑ 11.57 ± 3.00 % < 0.05 
Data are presented as mean ± SEM 
 
(Salem et al., 2017)  
 Control (Placebo) Treatment 
 Baseline Post-treatment p Baseline Post-treatment p 
FEV1 2.3 (0.6) 2.3 (0.6) Not significant 2.3 (0.7) 2.4 (0.7) Not significant 
FEV1 (% predicted) 81.1 (19.1) 80.8 (20.6) Not significant 78.1 (21.4) 85.5 (22.9) < 0.05 
PEF 76.6 (7.3) 78.5 (8.8) Not significant 73.7 (11.2) 81.4 (8.7) < 0.01 
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Table 3.3 Serum IgE outcomes in the clinical studies of Nigella sativa in patients with asthma 
 
Study reference Pulmonary function 
(Kalus et al., 2003)  
 Control (Placebo) Treatment 
 Baseline Post-treatment p Baseline Post-treatment p 
Serum IgE 387.6 (429) 337.9 (374) 0.02 291.9 (650) 269.6 (550) 0.14 
Data are presented as mean (SD) 
 
(Salem et al., 2017)  
 Control (Placebo) Treatment 
 Baseline Post-treatment p Baseline Post-treatment p 
Serum IgE 623.8 (802.5) 595.9 (752.5) 391.5 Not significant 393.8 (470.1) 322.0 (373.2) 0.01 
Data are presented as mean (SD) 
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1.14  Conclusion and rationale for the PhD work 
NS is a medicinal plant with a long history of use in asthma. The therapeutic 
benefits of NS were reported in different systems of traditional medicine as well 
as in modern scientific studies (pre-clinical and clinical studies). Pre-clinical 
studies showed a preliminary evidence for various preparations of NS (oil or 
extracts of aqueous/organic solvents) and TQ in asthma. Further clinical studies 
showed a promising activity of different NS preparations in patients with asthma 
but with variable NS dosage forms (oil, aqueous extract and whole crushed 
seeds).  
These pre-clinical and clinical studies had important limitations in the quality 
of design, sample size, and investigated outcomes. Also, the variability of the 
investigational NS preparations and its poor chemical characterisation were 
major drawbacks in these studies. 
Therefore, a specific method of pre-clinical characterisation of NS (chemical 
and pharmacological characterisation) was carried to find the best suitable active 
NS preparation that can be used in a clinical trial (Chapter 2 & 3). Followingly, 
NS was introduced as a complementary (add-on) treatment and assessed its 
efficacy in patients with asthma using a high-quality clinical trial (Chapter 4). 
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1.15  General aims and objectives of the dissertation 
1. Review the scientific literature for the current evidence for the medical use of 
Nigella sativa in asthma (Chapter 1). 
2. Obtaining a series of different Nigella sativa preparations, and chemically 
characterise them using phytochemical analytical techniques (Chapter 2). 
3. Pharmacological characterisation of the obtained Nigella sativa preparations 
using different pre-clinical in vitro models and compare the anti-
inflammatory/immunomodulatory (A/I) activity of these Nigella sativa 
preparations. Ultimately, to find the most suitable active extract that can be 
used for the clinical trial (Chapter 3). 
4. Investigate the clinical efficacy of the selected Nigella sativa preparation on 
asthma inflammation and outcomes in a high-quality clinical trial (Chapter 4).  
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2 Chapter 2. Phytochemical analysis: method 
development for extraction and analysis of different 
Nigella sativa preparations 
2.1 Introduction 
NS was used in various form of preparations in traditional medicine as well 
as pre-clinical and clinical studies. Different companies are producing NS 
products based on various extraction and processing methods. Also, many 
studies investigated the pharmacological activity of NS with poor chemical 
standardisation or characterisation. Ultimately, this can lead to a variability in the 
pharmacological activity of NS. Therefore, we intended to compare the 
phytochemical composition (Chapter 2) and the pharmacological activity of 
different NS preparations (Chapter 3); either prepared in our laboratory or 
imported as a commercial ready-made product from different companies. 
There is no official monograph defining the standard quality or composition 
of NS. Biological studies attribute the activity of NS mainly to TQ (Darakhshan et 
al., 2015). Therefore, TQ was selected as an indicator of NS quality, and NS 
preparations were characterised for the TQ level by High Performance Liquid 
Chromatography (HPLC). Additionally, Proton Nuclear Magnetic Resonance (1H 
NMR) was used to overview the variability in the phytochemical composition of 
the different NS extracts. 
2.2 Specific objectives 
• Obtain various types of NS preparations by either local laboratory 
extraction or importation of ready-made products of NS. 
• Quantification of the main active compound TQ among the NS 
preparations. 
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• Compare the TQ concentration level and 1H NMR fingerprints of the NS 
extracts. 
2.3 Materials and methods 
2.3.1 Solvents, reagents and chemicals 
• Ethanol absolute batch no. 11E160502, VWR. 
• Dimethyl sulfoxide-d6 NMR solvent, Sigma-Aldrich. 
• Thymoquinone (purity >98%), Cayman Chemicals. Catalogue number: 
CAY15039. 
2.3.2 Apparatus and instrumentation 
• HPLC instrument: WATERS 2695 separations module, attached to Waters 
996. Photodiode Array Detector.  
• Ependorff Minispin plus centrifuge, model 5453. 
• Fisher ultrasound bath, model FB 11020. 
• Rotamixer, rotary mixer, serial no. 8011. 
• HPLC 1.5ml amber screw vials, VWR. Cat no. 548-1367.  
• VWR NMR sample tubes, 5mm economy, 7” Length, 100MHz. 
• Bruker Avance 500MHz nuclear magnetic resonance (NMR) spectrometer 
(BrukerAnalytik, Rheinstetten, Germany). 
• Wet and Dry Grinder, Andrew James, model B00I0SF1N0. 
• Millex HA filter unit 0.45mm. 
• HPLC Column: phenomenex® P/NO 00F-4252-E0, Desc Luna 5u C18(2) 
100 Å, size 150x4.6mm 5 micron, S/NO 312985-48. 
45 | P a g e 
 
2.3.3 Software 
• Topspin software version 1.3 was used for NMR spectra observation and 
utilisation. 
• Microsoft Office Word and Excel 2010. 
2.3.4 Nigella sativa extracts collection and preparation 
Two main types of NS preparations were obtained in this study. First, the 
locally prepared extracts from crude NS seeds in our laboratory at the UCL 
School of Pharmacy. Second, a series of ready-made NS oil products from 
different companies were included. 
The crude seeds of NS were obtained from the spice market of Jeddah 
city in Saudi Arabia produced by Bafart company (Wadi Nimar, Al-Balad, Jeddah 
22236 - www.bafarat.sa). This product was selected because it has a high 
concentration of volatile oil content using Thin Layer Chromatography (TLC), 
according to my previous work for an analysis of 23 different NS samples from 
various origins as part of an MSc dissertation (Koshak, 2013). Apparently, this 
was probably due to the proper packaging and storage conditions of the product.  
Due to the discrepancies found in the literature about the type of NS 
preparation used in biological and clinical studies (such as aqueous extract, 
organic solvent extract, oil and powder), an approach of using different ratios of 
extraction solvents was used to obtain different combinations of water/alcohol 
soluble compounds. The crude seeds were used to prepare six different extracts 
(1-6) via different ratios of ethanol:water extraction solvents. Ten grammes of 
crushed NS were filled into six different 100 ml glass bottles. Then, different 
solvent ratios were used to produce the extracts by means of maceration for 
extracts 1-5 with frequent agitation at room temperature for three days, and by 
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means of decoction for extract 6 as following; Extract no.1 (100:0), 2 (80:20), 3 
(60:40), 4 (30:70), 5 (0:100), 6 (0:100 with continuous boiling for 30 minutes). 
After filtration, the ethanol was evaporated using a rotavap until complete 
dryness, while water removed by freeze-drying until complete dryness. On the 
other hand, commercial ready-made NS oil products were obtained from different 
producers (extracts 7-10) as shown in Table 4.  
Table 4. The list of obtained Nigella sativa preparations. 
NS preparation Extraction method or origin 
Extract 1 100% Ethanol 
Extract 2 80% Ethanol: 20% Water 
Extract 3 60% Ethanol: 40% Water 
Extract 4 30% Ethanol: 70% Water 
Extract 5 100% Water 
Extract 6 100% boiled water (30min boiling) 
Extract 7 Super Critical Fluid (SCF) extract by Sami Labs Ltd., India 
Extract 8 Cold pressed NS oil capsules by The Blessed Seeds, UK 
Extract 9 Cold pressed NS oil capsules by Sanct Bernhard, Germany 
Extract 10 
Cold pressed NS oil capsules by Marnys, Spain.  
(A licenced herbal product in Saudi Arabia) 
Extract 1-6; Laboratory prepared extracts from crude NS seeds using different 
ratios of combined extraction solvents. Extract 7-10; Commercial ready-made 
Nigella sativa oil extracts. 
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2.3.5 High Performance Liquid Chromatography method for analysis 
of thymoquinone in Nigella sativa preparations 
The High Performance Liquid Chromatography (HPLC) analysis method 
was developed using the approach of Hadad et al. (2012). The analysis was 
performed using a WATERS 2695 HPLC instrument. 20μl sample injected using 
gradient methanol-water (20-80, v/v) mobile phase over 10min and injection run 
time of 12min at flow rate of 1.5ml/min. 
The NS preparations were dissolved in 1 ml methanol inside 1.5 ml 
Eppendorf tubes separately, vortexed for 10 seconds and centrifuged for 2 min 
at 10000 rpm to separate any remaining of solid extract. Afterwards, the 
supernatant was transferred to an HPLC amber vial via 0.45mm filter for analysis 
with HPLC. The remaining solid extract was also analysed with HPLC to ensure 
complete extraction of TQ. 
After setting up the method on the HPLC instrument software, the samples 
were submitted in triplet, and the average reading results were used. Next, a 
calibration curve was made based on the area under curve readings of each 
sample peak. Microsoft Excel software was used to draw the calibration curve, 
and the level of TQ was determined accordingly. The individual HPLC 
chromatogram for each sample is provided in the appendix (Page 152).  
2.3.6 Proton Nuclear Magnetic Resonance method for the analysis 
of Nigella sativa preparations 
A Bruker Avance 500MHz nuclear magnetic resonance (NMR) 
spectrometer (BrukerAnalytik, Rheinstetten, Germany) equipped with a multi-
nuclear probe head with z-gradient was utilised to produce proton NMR analytical 
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spectra. 50mg of each NS extract (Extract 1-10) and 5mg of standard TQ was 
transferred into a 1.5ml Eppendorf tube. Then, samples were dissolved in 1.0ml 
of DMSO-d6, vortexed for 15 seconds, and ultrasonicated for 30 minutes, 
followed by further mixing on a rotary mixer. Afterwards, centrifugation was 
carried out for 5 minutes at 10,000 rpm. Next, 0.7 ml of the supernatant was 
transferred to a 5mm diameter NMR tube. These were submitted for NMR 
analysis. The NMR submission settings were adjusted to scan type: proton NMR, 
number of spins: 256 for optimum resolution, solvent: DMSO. 
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2.4 Results and discussion 
2.4.1 Extraction yield of Nigella sativa preparations from different 
extraction methods  
The extraction yields of 10 grammes of crude NS seeds using different 
solvent systems (Extract 1-6) are shown in Table 5. Apparently, Extract 1, in 
which 100% ethanol was used as a solvent, showed the highest yield among 
other preparations because of the relative high fatty acid content of NS which is 
more soluble in ethanol than water. 
Table 5. Extraction yield of the locally prepared Nigella sativa extracts 1-6. 
Preparations 
Extraction yield from 
10 g crude NS 
Percentage yield 
Extract 1 (100% ethanol) 3.25 g 32.5 % 
Extract 2 (80:20) 1.23 g 12.3 % 
Extract 3 (60:40) 1 g 10 % 
Extract 4 (30:70) 1.21 g 12.1% 
Extract 5 (100% water) 0.89 g 8.9 % 
Extract 6 (100% boiled water) 1.57 g 15.7 % 
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2.4.2 High Performance Liquid Chromatography analysis of 
thymoquinone in Nigella sativa preparations 
This experiment was conducted to determine the concentration of the main 
active compound thymoquinone (TQ) among all NS preparations. The method 
used to identify and quantify TQ in HPLC revealed the TQ peak at around 10.3 
min (Figure 3). Different serial dilutions of known concentrations of standard TQ 
solutions were prepared and analysed by HPLC (Table 6) to establish a 
calibration curve by Microsoft Excel (Figure 4). This curve was utilised to establish 
TQ levels among NS preparations (Table 7). 
The NS preparations had a variability in the TQ concentrations. This is 
attributed to the methods of extraction and preparation as well as origins of NS 
seeds. Extract 7 (prepared by supercritical fluid extraction method) appeared to 
have the highest concentration of TQ, followed by extract 10. Among the locally 
prepared extracts (extract 1-6), the 100% ethanolic extract 1 showed the highest 
level of TQ in comparison to the rest of the extracts. This is due to the solubility 
characteristics of TQ which is highly soluble in organic solvents. On the other 
hand, extracts 2-6 had very low or undetectable level of TQ, and this was 
confirmed by the absence of TQ peaks in the NMR analysis. 
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Figure 3. The standard TQ (0.2mg/ml) peak at 10.3 min in HPLC analysis.
 
 
Table 6. High Performance Liquid Chromatography peak areas of six known 
standard thymoquinone concentrations. 
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Figure 4. Calibration curve produced from the peak area results of six known 
concentrations (mg/ml) of standard thymoquinone. 
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Extract 1 84 28,577,583 0.371 0.4% 
Extract 2 36 1,522,845 0.004 0.01% 
Extract 3 80 3,996,096 0.037 0.04% 
Extract 4 109 486,202 ~0.005 ~0.005% 
Extract 5 138 124,386 < 0.005 < 0.005% 
Extract 6 125 N/A N/A N/A 
Extract 7 27 49,727,558 0.659 2.4% 
Extract 8 64 29,926,597 0.391 0.6% 
Extract 9 110 19,561,802 0.249 0.2% 
Extract 10 65 34,914,364 0.457 0.7% 
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2.4.3 Proton nuclear magnetic resonance analysis of Nigella sativa 
preparations 
The NS preparations and standard TQ were analysed by proton nuclear 
magnetic resonance (1H NMR). The typical 1H NMR peaks of TQ are shown in 
Figure 5. A comparison of all generated 1H NMR spectra is shown in Figure 6. 
Also, the presence of characteristic TQ peaks was assessed in NS preparations. 
As a result, extracts 1, 7, 8, and 10 appeared to have the characteristic peaks of 
TQ such as the 2 singlet peaks at 6.6 and 6.7ppm (Figure 6). However, the rest 
of extracts barely showed any presence of TQ peaks by matching with the 
reference standard TQ. These 1H NMR figures provided information on the 
presence/absence of TQ as well as a general overview of the variability in 
chemical compositions of the NS preparations. 
 
Figure 5. Proton nuclear magnetic resonance spectrum of thymoquinone using 
the nuclear magnetic resonance predictor online tool at nmrdb.org. 
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Figure 6. Comparison of proton nuclear magnetic resonance spectra of Nigella 
sativa preparations (Extracts 1-10) and thymoquinone. 
 
2.5 Conclusion 
Ten different preparations of NS were obtained via local preparation (at our 
laboratory) using different ratios of combined extraction solvents 
(water:methanol) along with the inclusion of commercial ready-made products. 
Using HPLC, high level of TQ was observed in the oily preparations due to the 
lipophilic nature of TQ. It was highly concentrated in the supercritical fluid extract 
(no. 7) followed by the commercial product of Marnys company (no. 10). 1H-NMR 
fingerprints showed variability in the phytochemical content between the extracts 
and confirmed the presence of TQ in the oily preparations. This variability in the 
chemical composition among NS preparations was linked to the biological activity 
(Chapter 3), and a the best suitable and biologically active preparation was used 













56 | P a g e 
 
3 Chapter 3: Pre-clinical (in vitro) screening 
3.1 Introduction 
The work of this chapter was done in collaboration with Dr Bernd Fiebich at 
the University Medical Center Freiburg in Germany. The goal of this work was to 
have a comparative screening for the general anti-
inflammatory/immunomodulatory (A/I) activity of the obtained NS preparations 
(Extracts 1-10, Chapter 2) in various pre-clinical in vitro models. There are several 
inflammatory mediators and signalling pathways from different human cells are 
involved in asthma inflammation as discussed in Chapter 1. Due to the 
capabilities of Dr Fiebich’s laboratory, certain targets were used for screening the 
activity of NS preparations on the expression of the inflammatory mediators IL-2, 
IL-6 and PGE2, as well as the inflammatory signalling protein phospho-p38. This 
was investigated in different laboratory-induced human cells including peripheral 
blood mononuclear cells (T-lymphocyte and monocytes cells), and A549 human 
lung epithelial cell line.  
The relevance of the selected targets was discussed in section 3.2. The 
preclinical in vitro activity (A/I) of NS preparations was investigated in this chapter. 
Consequently, the most active extracts that demonstrated potent A/I activity were 
selected for the clinical trial of NS in patients with asthma (Chapter 4). 
3.2 The relevance of the selected targets to asthma  
Interleukin-2 (IL-2) is an inflammatory cytokine mainly released by 
activated T cells (Hoyer et al., 2008). It is linked to asthma because it was found 
to be increased in the broncho-alveolar lavage fluid (BALF) of patients with 
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asthma (Virchow et al., 1996). Moreover, patients treated with inhaled IL-2 had 
asthma-like sign and symptoms (Loppow et al., 2007). 
Interleukin-6 (IL-6) is a small glycoprotein released from different cells of 
the immune system such as macrophages, dendritic, mast cells, B cells, some T 
cells, and non-leukocytes (such as epithelial cells, endothelial cells and 
fibroblasts) during an inflammatory or immune reaction. It is found to be a major 
pro-inflammatory mediator and a relevant target for several diseases (Hirano, 
1998). In patients with asthma, IL-6 was found at a high level in serum as well as 
in BALF (Yokoyama et al., 1995; Tillie-Leblond et al., 1999). IL-6 was elevated in 
induced sputum of allergic asthma patients (Neveu et al., 2010). There was an 
increase expression of IL-6 in bronchial epithelial cells of patients with asthma 
(Marini et al., 1992). Out of 170 adult patients with asthma, elevated serum IL-6 
was found in 54% of patients and that was associated with the use of high-dose 
inhaled corticosteroids (Ilmarinen et al., 2016). 
Prostaglandin E2 (PGE2) is one of the common prostanoids synthesised 
in humans and has an important role in the inflammatory cascade. Prostaglandins 
are produced by cyclooxygenase enzymes (COX-1 and COX-2). COX-1 is 
produced by most cell types in the body. COX-2 is expressed in response to 
stimuli mainly in antigen-presenting cells such as macrophages (Kaur et al., 
1999). PGE2 is considered a pleiotropic prostaglandin with stimulating or 
inhibiting properties. In general, PGE2 is commonly assumed as a 
proinflammatory mediator in several inflammatory diseases (Sastre and Del 
Pozo, 2012). PGE2 can induce Th2 cell development and Th2 cytokines profile 
secretion. Also, PGE2 can enhance the production of Immunoglobulin E (Kaur et 
al., 1999). However, PGE2 is also important because of the multiplicity of its 
effects on immune response in respiratory diseases. It is considered a major 
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mediator in the lower respiratory tract released mainly by epithelium and airway 
smooth muscle. It has a beneficial role in asthma via protection from lung smooth 
muscle proliferation and some anti-inflammatory effects (Sastre and Del Pozo, 
2012). PGE2 has an ability to reduce mast cells activity and relax smooth muscle 
(Torres, Picado and de Mora, 2015). In a clinical trial, inhaled PGE2 therapy had 
a protective role against the delayed response to allergen-induced asthma 
(Pavord et al., 1993). In patients with asthma, PGE2 showed bronchodilatory 
effects via inhibition of allergen-induced bronchoconstriction and some 
inflammatory mediators (Chung, 2005). 
 The inflammatory cell signalling p38 protein kinases is part of mitogen-
activated protein kinase (MAPK) family that plays a role in an inflammatory 
reaction and involved in some pro-inflammatory cytokines production (Hommes, 
Peppelenbosch and van Deventer, 2003). Inhibition of p38 may provide a wide 
range of anti-inflammatory effects which can be useful in several inflammatory 
diseases such as asthma (Newton and Holden 2003). Targeting p38 is a potential 
treatment option for asthma because it showed several beneficial effects such as 
inhibition of allergen-induced pulmonary eosinophilia, mucus overproduction, and 
lung hypersensitivity (Chung, 2011). Also, p38 inhibition may reduce 
corticosteroid insensitivity in severe asthma (Bhavsar et al., 2010). Detection of 
phospho-p38 stain was obvious in the epithelial cells of severe asthma patients 
(Liu et al., 2008). 
3.3 Specific objectives 
• Determination and comparison of the A/I activity of the prepared NS 
extracts (Chapter 2) using different in vitro cellular models. 
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• Selection of a suitable active extract that shows a potent A/I activity and 
can be used for the clinical trial of NS in asthma (Chapter 4). 
3.4 Material and methods 
3.4.1 NS preparations 
- Extracts 1-10 as mentioned in Chapter 2 (Table 4). 
3.4.2 Experimental materials and apparatus 
- (HRP)-coupled rabbit anti-goat IgG secondary antibodies, Santa 
Cruz. 
- 500ml of Roswell Park Memorial Institute medium (RPMI) 1640 
Media, GE Healthcare. 
- CELLSTAR® 50 ml Centrifuge Tubes, VWR. 
- Dimethyl sulfoxide (DMSO) solvent, Merck Millipore, Germany. 
- Dulbecco`s Phosphate Buffered Saline (DPBS), GIBCO®, Life 
Technologies. 
- Eppendorf Minispin plus centrifuge, model 5453. 
- Falcon® 24 Well Clear Flat Bottom TC-Treated Multiwell Cell Culture 
Plate (Product #353047), Corning B.V. Life Sciences. 
- Fisher ultrasound bath, model FB 11020. 
- Fresh human blood from healthy donors, University of Freiburg health 
centre. 
- Human IL-2 ELISA kit, R&D Systems. 
- Human IL-6 ELISA ready-SET-GO kit, eBioscience. 
- Human lung epithelial cell line (A549), Sigma-Adrich. 
- IMT-2 microscope, Olympus optical CO. LTD. 
- Interleukin-1β, human (hIL-1β) Product No. 11457756001, Roche Life 
Science. 
- LPS: L9516 Lipopolysaccharides (rough strains) from Salmonella 
enterica serotype typhimurium SL1181, Sigma-Aldrich. 
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- Lymphocyte Separation Medium (LSM 1077), The Cell Culture 
Company, PAA Laboratories GmbH. 
- Magellan Biosciences microplate reader, Dynex. 
- p.38 primary antibodies, Cell Signaling Co.  
- PGE2 Enzyme Immunoassay kit, Biotrend. 
- Pierce™ BCA Protein Assay Kit, Thermo Scientific™ [BCA Reagent 
A, BCA Reagent B, Albumin Standard Ampules 2mg/mL]. 
- Rotary mixer, Rotamixer serial no. 8011. 
- SEB: Staphylococcal enterotoxin B, Sigma-Aldrich. 
- Thermo Scientific™ Megafuge™ 3.0 RS. 
- Thermomixer basic, Cell Media Co. 
- Thermomixer compact, Eppendorf. 
- Thymoquinone (purity >98%), Cayman Chemicals. Catalogue 
number: CAY15039. 
3.4.3 Preparation of Nigella sativa extracts for in vitro testing 
Initially, a preparation step was carried out on all NS preparations for the 
in vitro screening. A 20mg of each NS preparation was dissolved in 1ml Dimethyl 
sulfoxide (DMSO) solvent inside 1.5ml Eppendorf tube with mixing on a rotamixer 
for 10 seconds. This is followed by centrifugation for 5 minutes at 1300rpm for 
separation of insoluble substances. Then, the clear supernatant was re-diluted in 
DMSO to produce three different dilutions as in the following concentrations; 
10µg/ml, 100µg/ml, and 500µg/ml as required for in vitro testing. Also, the 
standard TQ was prepared by using DMSO solvent to produce concentrations of 
0.1µM, 1µM, 5µM, and 10µM as required. As the molecular weight of TQ is 164 
g/mol, 1µM of TQ equals to 0.164µg/ml. 
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3.4.4 Isolation of human peripheral monocytes and T-lymphocyte 
cells for in vitro testing 
Human blood from three different healthy donors at the University Medical 
Centre Freiburg was obtained in 450 ml blood plastic bags. The isolation of 
human monocytes and T-lymphocyte cells were carried out according to a 
standardised protocol described by (Noble and Cutts, 1968; English and 
Andersen, 1974). In six CELLSTAR® 50ml Centrifuge tubes, 25 ml of 
Lymphocyte Separation Medium (LSM 1077) were added to each tube. Then, 20 
ml of human blood were carefully added into each tube. These tubes were applied 
to centrifugation with Thermo Scientific™ Megafuge™ instrument at 1800 rpm 
and acceleration 1 for 1 hour at room temperature. After centrifugation, the buffy 
coat was transferred to 50 ml CELLSTAR® tube prefilled with a 10ml of 
Dulbecco`s Phosphate Buffered Saline (DPBS) solution. This was completed to 
50 ml with the addition of more DPBS solution. Then, centrifugation for 10min at 
1600rpm, normal acceleration and room temperature. The supernatant was 
discarded, and DPBS was added on top the buffy coat layer to fill until 50 ml. 
Afterwards, centrifugation at 1200rpm for 10mi; supernatant discarded, and 20ml 
of DPBS was added with proper mixing. Additional DPBS was added to fill the 
tube until 50ml. The last step was repeated, and the supernatant was discarded, 
and the cells remained in the tube. Finally, the cells were re-suspended in 50 ml 
RPMI-1640 fortified with 10% human serum. Cells were counted using Olympus 
microscopy with the addition of 180 µL of Microscopy Solution (Trypan Blue 0.4%) 
and 20µl of sample cells solution. Further dilution with RPMI-1640 solution to 
maintain a proper cell density of 150-200 cells per ml. 
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3.4.5 Stimulation of monocytes and T-lymphocyte cells 
Sixteen of 24-well tissue culture plate were obtained and seeded with 1ml 
of cells solution in each well. This was incubated in 37c for 1 hour. Then the 
medium was changed with (RPMI 1640 + 10% human serum) and further 
incubated for another 1 hour at 37c. After that, a 5 µL of NS preparations (in 
concentrations 10, 100, 500µL) and standard TQ (10 µM) were added to their 
assigned well. In each plate, two wells were left without any extract to serve as 
positive (Cells+stimulant+DMSO) and negative (Cells+DMSO) reference. After 
30min incubation, 10µl of the stimulant LPS (Lipopolysaccharides, 10ng/ml) was 
added to each well (except –ve reference) of eight plates to stimulate monocytes. 
In another eight plates, 10 µl of the stimulant SEB (Staphylococcal enterotoxin B, 
100ng/ml) was added to each well (except –ve reference) to stimulate T-
lymphocyte cells. These plates were incubated at 37c overnight to allow 
stimulation of both monocytes and T-lymphocyte cells to release inflammatory 
mediators. In the next day, the supernatant was collected from each well into 
separate Eppendorf tubes and centrifuged to filter out any remaining cells. This 
step was further repeated, and the supernatant was stored at -80c for further 
analysis of the inflammatory mediators.   
3.4.6 Stimulation of human lung epithelial cells (A549)  
In four of 6-well plates containing A549 cells, 50 µl of each NS preparation 
(in both concentrations of 100 & 500 µg/ml) and standard TQ (10 µM) were added 
to plate wells. In each plate, two wells were left without any extract to serve as a 
positive control (Cells + stimulant + DMSO) and negative control (Cells + DMSO). 
After 30 min incubation, 20 µl of the stimulant IL-1β (10 µl /ml) was added to each 
well (except negative reference) to stimulate the A549 cells. These plates were 
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incubated at 37°c overnight to allow stimulation and production of inflammatory 
mediators. After incubation, the media was discarded and the cells were washed 
with DPBS for complete removal of media (cells are precipitated and attached to 
the bottom of wells). This is followed by a cell lysis step to break the cells and 
release the inflammatory mediators and cells proteins without protein 
degradation. This was done by the addition of 140 µl of a mixture of [2 ml lysis 
buffer + 2 µl protease inhibitor + 20 µl phosphatase inhibitor] in each well. 
Followed by proper mixing and scratching over a box of ice for 2 min. Then, the 
supernatant in each well was transferred into separate Eppendorf tubes and 
heated to 90°c on a thermomixer at 300rpm for 5 min. Afterwards, the protein 
estimation step was carried (3.3.7). 
3.4.7 Protein estimation in A549 cells 
This step was carried as preliminary step for quantification of phospho-p38 
in the following immunoblotting step (3.4.8). The protein content was measured 
according to the manufacturer instructions (Pierce™). A solution of a mixture of 
BCA Reagent A and BCA Reagent B (ratio 50:1) was prepared in the required 
amount that is 200 µl for each well. In a 96-well plate, a 200 µl of this mixture was 
added to all test wells. BCA Albumin Standard was added in different amounts 
(1, 2, 4, 8, 10, 20 µl) to be used as a standard curve for estimation of protein from 
samples. All samples were diluted with 1 ml of lysis buffer, and 10 µl of each 
sample was added to its corresponding well. The plate was placed on a 
thermomixer for 30min at 95c and 300rpm. Accordingly, the protein amount was 
detected by extrapolating the wavelengths readings of samples to the standard 
BCA Albumin readings, using DYNEX Magellan Biosciences microplate reader. 
This information was used in immunoblotting. 
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3.4.8 Immunoblotting (Western Plot) for phospho-p38 inflammatory 
signalling proteins 
This was carried on the A549 cells exudates to quantify the expression of 
phospho-p38 inflammatory signalling proteins. This was done to explore a 
possible mechanism of the anti-inflammatory action of NS according to the 
methodology of (Olajide et al., 2013). In phospho-p38 signalling protein detection, 
rabbit anti-phospho p38 MAPK poly-clonal antibody (Cell Signalling, Schwalbach, 
Germany) used as primary antibodies and goat anti-total p38 MAPK (Santa Cruz, 
Heidelberg, Germany) as secondary antibodies. Quantification of the proteins 
was done by ImageJ software after normalisation with total protein. This was 
done as a single experiment for screening NS preparations. Then, the same 
experiment was replicated on selected NS preparations using new A549 cell line 
in each experiment.  
3.4.9 Enzyme-linked immunosorbent assay for interleukin-6, 
interleukin-2 and Prostaglandin E2 determination 
Measurements of the levels of the pro-inflammatory mediators: IL-6, IL-2, 
and PGE2 were performed by enzyme-linked immunosorbent assay (ELISA) kits 
according to the manufacturer’s instructions (Human IL-6 ELISA ready-SET-GO 
kit by eBioscience; Human IL-2 ELISA kit by R&D Systems; PGE2 Enzyme 
Immunoassay kit by Biotrend). All experiments were replicated at least three 
times with different new blood donor or cell line. 
3.4.10 Statistical analysis 
The results were statistically analysed using one-way ANOVA with post-hoc 
Dunnett’s test to investigate significant effects of each NS preparation against the 
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control group. For each experiment, P value <0.05 was considered statistically 
significant. 
3.5 Results and discussion 
3.5.1 Effect of Nigella sativa preparations on human T-lymphocyte 
cells inflammatory mediators 
The effect of NS preparations on the release of the inflammatory mediators 
IL-2, IL-6 and PGE2 was investigated in SEB-induced human T-lymphocyte cells. 
Initially, three different concentrations of NS preparations were used in this 
experiment (10, 100 and 500 µg/ml). The optimum concentrations were found to 
be 100 µg/ml for most NS preparations. This was due to the poor effect appeared 
by using the concentration of 10µg/ml (no significant inhibition) and the very high 
effect shown by the concentration of 500µg/ml (complete inhibition of cytokines 
release) by most NS preparations.  
There was a suppression of IL-2 release from T-lymphocyte cells by all NS 
preparations, which was noteworthy (by more than 50%) with extracts 1, 2, 3, 5, 
7, 8, and 10 (Figure 7). This suppressive effect of NS on IL-2 release from human 
T-lymphocyte cells is not reported in the literature. However, in an animal study, 
there was a suppression of serum IL-2 in mice by NS fixed oil (Abbas et al., 2005). 
This suppressive effect of IL-2 release from T lymphocyte cells may be beneficial 
in the context of asthma as it is considered a pro-inflammatory mediator and 
found in a high level in BALF of patients with asthma.    
IL-6 release from T-lymphocyte cells was markedly reduced (by more than 
50%) with the oily extracts 1, 7, 10. (Figure 8). Conversely, IL-6 release from T-
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lymphocyte cells was increased with water or mixed (water/oil) extracts 3, 4, 5, 
and 6. This effect of NS on IL-6 release from human T-lymphocyte cells is not 
reported in the literature. This suppressive effect of IL-6 release from T 
lymphocyte cells may be beneficial in the context of asthma as it is considered a 
pro-inflammatory mediator and found in a high serum level among patients with 
asthma.    
PGE2 release from T-lymphocyte cells was inhibited markedly (by more 
than 50%) only with the oily extracts 7 and 10 (Figure 9). Conversely, there was 
a marked stimulation of PGE2 release (by more than 150%) with water/ethanol 
extracts, and particularly with pure water extracts (by up to 10 times). 
Interestingly, there was a positive relationship between the NS extracts prepared 
by water (low TQ level) and the release of the PGE2 from T-lymphocyte cells. 
This suppressive effect of NS on PGE2 release from human T-lymphocyte cells 
is not reported in the literature. However, the NS volatile oil administration 
significantly lowered the plasma level of PGE2 in rats (Salim, 2010). In an in vitro 
cyclooxygenase-1 (COX-1) and -2 (COX-2) assays, TQ caused a general anti-
inflammatory activity via inhibition of COX-1 and COX-2 catalysed PGE2 
production (Marsik et al., 2005). Carvacrol, a volatile oil constituent of NS, 
inhibited the release of PGE2 catalysed by COX-2 (Landa et al., 2009). This 
suppressive effect of PGE2 release from T lymphocyte cells may be considered 
a favourable effect due to the general pro-inflammatory properties of PGE2 and 
the enhancement effect of PGE2 on Th2 and IgE responses.  
Interestingly, there was a positive relationship between the TQ level of the 
oily NS preparations and the inhibition of the inflammatory mediators IL-2, IL-6 
and PGE2.  
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Figure 7. The effect of Nigella sativa preparations on interleukin-2 production by 
SEB-induced T-lymphocyte cells (n=3). 
 
Significant effects are indicated by an asterisk (***P<0.001). 
 
Figure 8. The effect of Nigella sativa preparations on interleukin-6 production by 
SEB-induced T-lymphocyte cells (n=3). 
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Figure 9. The effect of Nigella sativa preparations on prostaglandin E2 production 
by SEB-induced T-lymphocyte cells (n=3). 
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3.5.2 Effect of Nigella sativa preparations on Monocytes 
inflammatory mediators 
The effect of NS preparations on the release of inflammatory mediators IL-
6 and PGE2 was investigated in LPS-induced monocytes. The concentration of 
100µg/ml for most NS preparations was used according to the findings of the 
previous experiment on T-lymphocyte cells. 
There was a suppression of IL-6 release from monocytes with most 
extracts, and a marked inhibition occurred (by more than 50%) with the oily 
extracts 1, 7, 8 and 10 (Figure 10). This effect by NS is not reported in the 
literature.  However, TQ alone suppressed the expression of IL-6 from 
Mycobacterium tuberculosis infected human monocyte THP-1 cells (Mahmud et 
al., 2017). TQ inhibited the production of IL-6 in LPS-activated murine 
macrophage-like RAW264.7 cells (Hossen et al., 2017). This suppressive effect 
of IL-6 release from monocyte cells may be beneficial in the context of asthma as 
it is considered a pro-inflammatory mediator and found in a high level in the serum 
of patients with asthma.    
There was a marked suppression of PGE2 release from monocyte cells 
(by more than 50%) with the oily extracts 1, 7, 8 and 10 (Figure 11). This 
suppressive effect of NS on PGE2 release from human monocyte cells is not 
reported in the literature. This suppressive effect of PGE2 release from monocyte 
cells may be considered a favourable effect due to the general systemic pro-
inflammatory properties of PGE2 and the enhancement effect of PGE2 on Th2 
and IgE responses.  
70 | P a g e 
 
The marked inhibitory activity of the oily extracts may be attributed to the 
high TQ content particularly in the oily extracts 7 and 10, which showed an 
inhibitory action at 10 µM of TQ. 
Figure 10. The effect of Nigella sativa preparations on interleukin-6 production by 
LPS-induced monocytes (n=3). 
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Figure 11. The effect of Nigella sativa preparations on prostaglandin E2 
production by LPS-induced monocytes (n=3). 
 
Significant effects are indicated by asterisks (*P<0.05, ***P<0.001). 
3.5.3 Effect of Nigella sativa preparations on inflammatory 
mediators from A549 lung epithelial cells  
There was no significant inhibition of IL-6 release by all NS preparations 
in IL-1β-induced A549 lung epithelial cells (Figure 12). The concentration of 
100µg/ml for most NS preparations was used according to the findings of the 
previous experiment on T-lymphocyte cells. 
A previous study demonstrated that NS fixed oil significantly suppressed 
mRNA IL-6 in whole lung tissue of rats (Shahzad et al., 2009). Moreover, TQ 
suppressed the expression of IL-6 from M. tuberculosis infected A549 cells 
(Mahmud et al., 2017). The inhibitory effects of TQ were also shown on IL-6 
expression from Human proximal tubular epithelial cells stimulated with advanced 
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suppression of IL-6 may possess beneficial anti-inflammatory effects in bronchial 
epithelial cells of asthmatic patients (Mattoli, Marini and Fasoli, 1992). Unlike 
beta-agonists (a conventional treatment in asthma), which can enhance IL-6 
expression in the lung, NS in this experiment had a mild inhibitory effect of on IL-
6 release like steroids (Edwards et al., 2007). 
Conversely, the release of PGE2 was increased markedly (by more than 
150%) with extracts 1, 2, 6, 7, 8, and 10 (Figure 13). This stimulatory effect of NS 
on PGE2 release from A549 human lung epithelial cells is not reported in the 
literature. However, such finding of increased PGE2 release was shown in 
perfused guinea-pig lung preparation used NS oil (Saleh, ElDenshary and 
Mahran, 2012). Interestingly, the increased PGE2 release by TQ-rich NS 
preparations may have an encouraging effect in the context of asthma as several 
studies showed that PGE2 may possess beneficial local protective and 
bronchodilatory effects in the airways of the lung (3.2).  
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Figure 12. The effect of Nigella sativa preparations on interleukin-6 production by 
interleukin-1β-induced A549 cells (n=3). 
 
 
Figure 13. The effect of Nigella sativa preparations on prostaglandin E2 
production by interleukin-1β-induced A549 cells (n=3). 
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3.5.4 Summary of the activity of Nigella sativa preparations in 
preclinical in vitro models. 
The oily extracts 7 (a supercritical fluid extract) and 10 (a commercial oil 
product by Marnys, Spain), which are characterised by the highest level of TQ, 
showed the most remarkable effect on suppressing the inflammatory mediators 
IL-2, IL-6 and PGE2 from human T-lymphocyte cells. In addition, these two 
extracts showed a marked suppression of IL-6 and PGE2 release from human 
monocytes. The other oily extracts 1, 2 and 8 had also shown a suppression of 
inflammatory mediators in T-lymphocyte and monocytes but in a limited number 
of mediators compared to extracts 7 and 10. On the other hand, the oily extracts 
1, 2, 7, 8, 10 had a remarkable enhancement effect on the release of PGE2 from 
A549 human lung epithelial cells (Table 8). 
Therefore, extracts 7 and 10 showed the most potent and favourable 
effects in the context of asthma, due to their anti-inflammatory actions by limiting 
the release of inflammatory mediators in human immune cells (T-lymphocyte and 
monocyte cells) as well as their possible bronchodilatory effect by enhancement 
of PGE2 release in A549 human lung epithelial cells. 
  
75 | P a g e 
 
Table 8. Summary of the most active Nigella sativa preparations by more than 
50% suppression or 150% enhancement of inflammatory mediators in cellular in 
vitro models of inflammation (n=3). 
Sample 
T-lymphocyte cells Monocytes A549 
IL-6 IL-2 PGE2 IL-6 PGE2 PGE2 
Extract 1 ↓ ≥ 50% ↓ ≥ 50%  ↓ ≥ 50% ↓ ≥ 50% ↑ ≥ 150% 
Extract 2  ↓ ≥ 50%    ↑ ≥ 150% 
Extract 7 ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↑ ≥ 150% 
Extract 8  ↓ ≥ 50%  ↓ ≥ 50% ↓ ≥ 50% ↑ ≥ 150% 
Extract 10 ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↓ ≥ 50% ↑ ≥ 150% 
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3.5.5 Effect of Nigella sativa preparations on p38 mitogen-activated 
protein kinase signalling pathway in A549 cells 
Investigation of the NS activity on p38 mitogen-activated protein kinase 
(MAPK) inflammatory signalling pathway inhibition was done to explore a 
possible mechanism of NS anti-inflammatory activity. In IL-1β-induced A549 
cells, extracts 8, and 10 showed a remarkable inhibition of phospho-p38 protein 
expression, but this was not correlated with TQ (Figure 14 and 15). The results 
of phospho-p38 were normalised with total p38 protein for verification (Figure 15). 
Additional experimental repeats were done with the most active NS preparations 
(extract 8 and 10) to verify their activity on p38 MAPK signalling pathway inhibition 
(Figure 16). 
This finding of p38 MAPK signalling pathway inhibition in A549 cells was 
not reported in the literature. However, TQ blocked the induction of p38 MAPK 
phosphorylation in LPS activated murine macrophage-like RAW264.7 cells and 
inhibited LPS mediated upregulation of phospho-p38 in mouse peritoneal primary 
macrophages (Hossen et al., 2017). Also, TQ inhibited TNF-α-induced phospho-
p38 expression in human rheumatoid arthritis synovial fibroblasts (Umar et al., 
2015). In contrast, TQ caused a dose-dependent increase of phospho-p38 
expression in rabbit articular chondrocytes (Goldstein and Gabriel, 2005). The 
anti-tumour effect of TQ was found to be mediated through induction of p38 in 
breast cancer cell line (Woo et al., 2013). This contradicting effect of TQ on p38 
signalling pathway might be due to differences in cell type.  
There was a mild suppressive effect by TQ and a remarkable 
downregulation by the oily extracts 8 and 10 on the expression of phospho-p38 
in A549 cells. This may indicate that other compounds in the TQ-rich extracts 8 
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and 10 may play an active role in inhibition of p38 MAPK signalling pathway rather 
than TQ alone. This may indicate that the mechanism of the anti-inflammatory 
effect of NS is possibly through the inhibition of p38 MAPK signalling pathway. 
Thus, NS may act as a p38 inhibitor which has possible therapeutic benefits in 
inflammatory conditions (Goldstein and Gabriel, 2005). In future, further 
investigations are encouraged to elucidate another possible mechanism of anti-
inflammatory action through other pathways. 
Figure 14. The preliminary inhibitory activity of Nigella sativa preparations on 
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Figure 15. Western blot bands of the effect of Nigella sativa preparations on p38 signalling pathway in interleukin-1β-induced A549 cells. 
The phospho-p38 results was normalised by total p38 results (n=1). 
 Extracts 1-3 Extracts 4-5 Extracts 6-8 Extracts 9-10 Extract 11 and TQ 
Phospho- 
p38  




 1    2   3   4    5   6   7   8 
 
  9    10    11   12   13   14 
 
 15  16 17 18 19  20 21 22 
 
  23   24   25   26   27  28 
 
  29  30  31  32  33  34  35 
Numbers 
identification 
1. -ve: DMSO 
2. +ve: IL-1β 10 U/ml 
3. Extr. 1   100  µg/ml 
4. Extr. 1   500  µg/ml 
5. Extr. 2   100  µg/ml 
6. Extr. 2   500  µg/ml 
7. Extr. 3   100  µg/ml 
8. Extr. 3   500  µg/ml 
9. -ve: DMSO 
10. +ve: IL-1β 10 U/ml 
11. Extr. 4   100  µg/ml 
12. Extr. 4   500  µg/ml 
13. Extr. 5   100  µg/ml 
14. Extr. 5   500  µg/ml 
15. -ve: DMSO 
16. +ve: IL-1β 10 U/ml 
17. Extr. 6   100  µg/ml 
18. Extr. 6   500  µg/ml 
19. Extr. 7   100  µg/ml 
20. Extr. 7   500  µg/ml 
21. Extr. 8   100  µg/ml 
22. Extr. 8   500  µg/ml 
23. -ve: DMSO 
24. +ve: IL-1β 10 U/ml 
25. Extr. 9    100  µg/ml 
26. Extr. 9    500  µg/ml 
27. Extr. 10  100  µg/ml 
28. Extr. 10  500  µg/ml 
29. -ve: DMSO 
30. +ve: IL-1β 10 U/ml 
31. Extr. 11  100  µg/ml 
32. Extr. 11  500  µg/ml 
33. TQ 1     1 µM 
34. TQ 1     5 µM 
35. TQ 1   10 µM 
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Figure 16. The effect of selected Nigella sativa preparations on phospho-p38 
signalling pathway inhibition in activated A549 cells (n=2). 
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3.6 Conclusion 
The results of this chapter, provided direct in vitro evidence that the release 
of some cytokines with inflammatory properties (IL-2, IL-6, PGE2) from human 
immune cells (including T-lymphocytes and monocytes), were suppressed by the 
oily NS preparations. These cytokines are normally upregulated in patients with 
asthma, and such suppressive effect by NS may mimic corticosteroids in inducing 
remission of asthmatic symptoms. 
However, there was a variability in the anti-inflammatory / 
immunomodulatory effects of different NS preparations on the expression of 
inflammatory mediators (IL-6, IL-2, PGE2) in human T-lymphocyte, monocyte 
and A549 lung epithelial cells. Apparently, the oily preparations (especially 
extract 7 and 10) appeared to be among the most potent active extracts by 
inhibiting inflammatory mediators in more than one type of human cells. There 
was a positive relationship between the level of TQ and inhibition of inflammatory 
mediators in T-lymphocyte and monocyte cells. Interestingly, the oily 
preparations (including extracts 7 and 10) showed an increase in PGE2 
production in A549 cells, which may possess a favourable effect in the context of 
asthma. Also, suppression of the inflammatory p38 signalling pathway as a 
possible mechanism of anti-inflammatory action was discovered in this study, but 
this inhibition was not correlated with TQ itself but inhibited by TQ-rich extracts 
(such as extract 10). In the end, extracts 7 and 10 appeared to be the most potent 
preparations recommended for the clinical trial.  
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4 Chapter 4. The clinical trial* 
4.1 Introduction 
Due to the high incidence of asthma, suboptimal control of asthma, and poor 
adherence to asthma medications, there is a need for novel strategies to improve 
asthma control (Chapter 1). Empirical evidence suggests potential benefits of NS 
in pre-clinical asthma models and preliminary clinical trials (Chapter 1). However, 
the current clinical trials of NS in asthma had limitations such as low standard of 
trial design, small sample size, limited investigated outcomes, and poor chemical 
characterisation of the NS preparation used in most trials (Chapter 1). 
Therefore, we intended to investigate the effects of NS oil supplementation 
on asthma outcomes and biomarkers in a phase-II randomised double-blind 
placebo-controlled clinical trial (RDBPCT) with a higher number of sample size 
and biomarkers. Exclusively, the investigational product in this trial was 
chemically and pharmacologically characterised preparation of NS. Based on the 
results of Chapter 2 and 3, extracts 7 and 10 appeared to be the most active NS 
preparations, but extract 10 was used in the clinical trial due to the logistical 
suitability as discussed in this chapter. This trial was important to assess the 
efficacy and safety of NS oil supplementation for patients with asthma in a well-
designed study. The clinical trial design, implementation plan, ethical and 
logistical considerations, and results were discussed in details in this chapter. 
 
*Part of the results in this chapter is published; 
Koshak, A., Wei, L., Koshak, E., Wali, S., Alamoudi, O., Demerdash, A., Qutub, 
M., Pushparaj, P. N. and Heinrich, M. (2017) ‘Nigella sativa Supplementation 
Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, 
Placebo-Controlled Trial’, Phytotherapy Research. doi: 10.1002/ptr.5761. 
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4.2 Specific objectives 
• To develop the design and implementation plan and highlight the ethical 
considerations of the NS clinical trial in patients with asthma.  
• To study the efficacy of NS supplementation in patients with asthma, using 
a properly designed clinical trial. 
4.3 Material and Methods 
4.3.1 Clinical trial design  
The design and outcome choice of the clinical trial (Table 9) was 
developed according to the guidance on clinical investigation of medicinal 
products for the treatment of asthma (European Medicines Agency, 2013), 
Asthma Outcome Measures (Shen, Johnston and Hays, 2011), and Asthma 
outcomes: Biomarkers (Szefler et al., 2012). The design has been discussed and 
developed along with three co-investigators at the study site (King Abdulaziz 
University Hospital “KAUH”, Jeddah, Saudi Arabia) according to the best 
applicable practice in the context of the planned study; Prof Emad Koshak 
(consultant in allergy, asthma and immunology), Prof Siraj Wali (consultant in 
pulmonary and sleep medicine), and Prof Omer Alamoudi (consultant in 
pulmonary medicine). Also, the secondary supervisor at UCL Dr Li Wei 
(epidemiology and medical statistics) and the UCL Research Ethics Committee 
further reviewed the trial design. 
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Table 9. Summary of the clinical trial design of Nigella sativa oil supplementation 
on asthma inflammation and outcomes 
Title 
Potential Benefits of Nigella sativa Oil Supplementation 
on Asthma Inflammation and Outcomes 
Phase Phase II clinical trial 
UCL Number UCL REC project ID number 6419/002 
Online registration ClinicalTrials.gov: NCT02407262 
Research type 
Prospective randomised (1:1) double-blind placebo-
controlled parallel-group clinical trial (RDBPCT). 
Sample size 80 participants 
Age range 18-65 years of age 
Study locations 
 
King Abdulaziz University Hospital (KAUH) including 




Marnys® Cuminmar (Nigella sativa oil, 500mg).  
Dose: 500mg twice daily for 4 weeks. 
Placebo 
Olive oil (pharmaceutical excipient grade), 500mg 
capsules produced by Marnys. 
Dose: 500mg twice daily for 4 weeks. 
Treatment duration 4 weeks 
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Primary outcomes -Asthma Control Test (ACT) 
Secondary 
outcomes 
-Pulmonary function test (PFT) 
-Absolute blood eosinophil count 
-Blood biomarkers of airway inflammation 
Primary safety 
endpoint 
Occurrence of any severe side effect at any point 
during the intervention period 
Inclusion criteria 
 
-Adult male/female (age 18-65 years) 
-Asthma diagnosis according to the GINA guidelines 
(Global Initiative for Asthma, 2017) 
-Asthma symptoms not fully controlled based on ACT 
score from 5 to 24 
-No severe asthma exacerbation in the last four weeks 
-Able to obtain consent 
Exclusion criteria 
 
-Patients with serious co-morbid conditions such as; 
cancer, renal, hepatic, cardiovascular, gastrointestinal 
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-Currently taking any form of NS 
-Known history of hypersensitivity to NS or olive oil 
-Taking medications that may interact with NS or olive 
oil; oral corticosteroids, anticoagulant, antiplatelet, CNS 
depressants, and immunosuppressant drugs. 
 
4.3.1.1  Sample size estimation  
The sample size was estimated based on the expected improvement of an 
average primary outcome (ACT) from 17 to 20 (Nathan et al., 2004). Using 
nQuery Advisor software for power calculation, it is estimated to have at least 40 
patients in each group of both treatment and placebo based on the following 
parameters: 
• Significance level: 0.05 
• Two-sided independent t-test 
• Mean1 (average ACT of not well-controlled population): 17 
• Mean2 (estimated ACT): 20 
• Difference in mean (estimated effect): 3  
• Common SD: 4.7 
• Effect size: 0.638 
• Power: 80 % 
4.3.1.2  Interventions and compliance check 
In the treatment group, the interventional product was softgel capsules of 
Nigella sativa oil (Figure 17). It was characterised by 0.7% thymoquinone at our 
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labs (UCL School of Pharmacy, London, UK) by High Performance Liquid 
Chromatography (HPLC). It was produced according to pharmaceutical GMP 
standards by Marnys® (Cartagena, Spain; brand name: CUMINMAR; batch 
number: L885) and is a licensed product of the Saudi Food and Drug Authority 
(SFDA) as a herbal medicinal product. The placebo group received similar 
capsules of virgin olive oil (produced in identical appearance by Marnys®, batch 
number: M398). Both groups received a dose of one capsule (500mg oil) twice 
daily for four weeks. Patient compliance with interventions was determined by 
counting the remaining capsules at the final visit. 
Figure 17. The investigational products (Nigella sativa oil capsules as the 
treatment and olive oil capsules as the placebo) 
 
 
4.3.1.3  Blinding and randomisation 
Both the investigator and the patients were blinded to treatment or placebo 
groups. An external medical scientist created a randomisation list (with a unique 
code for each trial medication) using Sealed Envelope Limited online tool in 
random permuted blocks of sizes 2 and 4 (Sealed Envelope Ltd, 2016). These 
Treatment      Placebo 
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mixed block sizes were used to reduce the selection bias and achieve a better 
balance in the allocation of participants. Co-investigators enrolled participants 
from their clinics and the principal investigator allocated patients to their 
concealed study medications. The packaging label of study medications 
contained the randomisation code, study title, expiration date, date of packaging, 
and contact information.  
4.3.1.4  Participant recruitment and obtaining consent 
Adult asthmatic patients were invited to the trial from the study clinics of 
respiratory, allergy, and family medicine or by contacting registered asthmatic 
patients within the hospital’s directory of KAUH. After a patient accepted to 
participate and was checked for the fulfilment of eligibility criteria, the investigator 
introduced and discussed the informed consent sheet with the patient. This 
informed consent included a description of the study procedures, risks and 
benefits of participation. Also, the patient was informed that participation in this 
study is voluntary and he/she have the right to withdraw at any time without giving 
a reason. Afterwards, the patient was given enough time to decide on 
participation. Once the patient decided to participate, he/she was asked to sign a 
consent form along with the researcher signature and handled a copy of the 
consent. The original copy was kept in a safe and locked place. 
4.3.1.5  Primary outcome 
The primary outcome was the ACT score. This was chosen because of the 
current asthma guidelines, including the Global Initiative for Asthma, recognised 
asthma control as a principal component for asthma management (Global 
Initiative for Asthma, 2017). Traditionally, asthma practice guidelines were 
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focused on optimising lung function, minimising symptoms and reducing 
exacerbations. Pulmonary function was regarded as the primary outcome in 
previous guidelines, until the discovery of a poor correlation between lung 
function, inflammation and symptoms. Clinical practices and trials have focused 
increasingly on assessing asthma control (Shen, Johnston and Hays, 2011). The 
Global Initiative for Asthma guidelines recommends using one of the numerical 
“asthma control” tools such as the Asthma Control Test (ACT) and the Asthma 
Control Questionnaire (ACQ) for scoring the level of asthma control and patients’ 
progress (Global Initiative for Asthma, 2017). The ACT is one of the best validated 
instrument to measure asthma control (Cloutier et al., 2012). It is commonly used 
by the Saudi Initiative for Asthma (SINA) Group and considered to be a 
favourable option because it is short and easy to fill by the patient (Reddel et al., 
2009). An Arabic validated version of the ACT (Figure 18) was used in this study 
(Lababidi, Hijaoui and Zarzour, 2008). 
The ACT consists of five questions with a total score of 5-25. Each 
question (Q1-Q5) scaled from 1 to 5 (Nathan et al., 2004). A total score of 25 is 
regarded as complete control, and a change of 3 points is considered to be 
clinically important (Global Initiative for Asthma, 2017). The following are the five 
questions of the ACT:   
1. Q1=In the past 4 weeks, how much of the time did your asthma keep you 
from getting as much done at work, school or home? 
2. Q2=During the past 4 weeks, how often have you had shortness of 
breath? 
3. Q3=During the past 4 weeks, how often did your asthma symptoms 
(wheezing, coughing, shortness of breath, chest tightness or pain) wake 
you up at night or earlier than usual in the morning? 
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4. Q4=During the past 4 weeks, how often have you used your rescue 
inhaler or nebuliser medication? 
5. Q5=How would you rate your asthma control during the past 4 weeks?  
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4.3.1.6  Secondary and exploratory outcomes 
There are several outcomes can be used in clinical trials of asthma. Based 
on the feasibility and availability as well as co-investigators recommendations for 
the choice of other than primary outcomes, it was agreed to use the following: 
1- Secondary outcomes: 
a. Pulmonary function (FEV1 as % predicted). 
b. Absolute blood eosinophil count. 
2- Exploratory outcomes: 
a. Individual questions of ACT 
b. Pulmonary function (PEF and FEF25-75% as % predicted) 
c. Total serum Immunoglobulin E (IgE) 
d. Serum cytokines 
4.3.1.7 Pulmonary Function Test 
Pulmonary function test (PFT) was performed using the “Easy on-PC” 
spirometer (ndd Medical Technologies, Inc., Switzerland) as shown in Figure 19. 
The pulmonary function for each patient was measured in triplicate, and the best 
reading was recorded. Spirometry is used for pulmonary function testing since it 
is considered one of the important tools to measure asthma control (Shen, 
Johnston and Hays, 2011). It provides an objective measure of airway limitation 
caused by smooth muscles contraction or structural abnormalities (Shen, 
Johnston and Hays, 2011). However, due to its poor association with asthma 
symptoms, it may be used to provide complementary information on asthma 
control (Shen, Johnston and Hays, 2011).  
The forced expiratory volume in 1 second (FEV1) is the amount of air that 
can be forcefully blown out in a second (Thillai and Hattotuwa, 2012). It used to 
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predict airway obstruction as well as response to the bronchodilatory effect of 
asthma medications (Thillai and Hattotuwa, 2012). It is considered the most 
appropriate parameter of spirometry for asthma control monitoring (European 
Medicines Agency, 2013). Predicted FEV1 is derived from FEV1 when baselines 
characteristics (gender, race, age and height) is considered. The normal level of 
predicted FEV1% is >80% (British Thoracic Society/Scottish Intercollegiate 
Guidelines Network, 2016). FEV1 starts to improve within days in patients taking 
regular corticosteroids therapy and the minimal important difference for 
improvement in predicted FEV1% is about 10% (Global Initiative for Asthma, 
2017).  
PEF (Peak expiratory flow) is a parameter of the maximal flow achieved 
during the maximally forced expiration initiated at full inspiration (Thillai and 
Hattotuwa, 2012). It may indicate an airway obstruction, but it is less important 
than FEV1 (Shen, Johnston and Hays, 2011). PEF has no advantage over FEV1 
in reproducibility, has limited reference values for many populations, and may 
underestimate the level of airway obstruction in patients with airway remodelling 
(Reddel et al., 2009). The normal level of predicted PEF% is >80% (British 
Thoracic Society/Scottish Intercollegiate Guidelines Network, 2016). 
FEF 25-75% (Forced Expiratory Flow between 25-75% of pulmonary 
volume) is a value of average flow over the middle portion of the flow-volume 
curve (Thillai and Hattotuwa, 2012).  It provides important information regarding 
small airway obstruction (Thillai and Hattotuwa, 2012). 
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Figure 19. Easy on-PC spirometer device for pulmonary function test. 
 
4.3.1.8  Blood biomarkers 
Biomarkers of airway inflammation provide additional objective 
measurements in asthma clinical trials (Shen, Johnston and Hays, 2011). In this 
study, total blood eosinophil count and total serum IgE were used as secondary 
outcome measures. Changes in multiple serum inflammatory mediators were 
also explored in this study. 
Eosinophil cells play a major role in asthma inflammation, and blood 
eosinophil count is considered to be a vital biomarker in asthma trials (Szefler et 
al., 2012). Several studies found a positive relationship between blood eosinophil 
count and the risk of exacerbations (Hambleton and Pavord, 2016). Total 
peripheral eosinophil count was positively correlated with asthma severity level 
in adult asthmatics (Koshak and Alamoudi, 1999). High blood eosinophil level 
(≥250  cells/uL) was associated with higher bronchial hyperresponsiveness, poor 
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pulmonary function and higher total serum IgE level in the analysis of 474 
asthmatics (Nadif et al., 2016). Total serum Immunoglobulin E (IgE) is associated 
with asthma. It is considered to be a complementary biomarker in allergic asthma 
and as an outcome in interventional studies (Szefler et al., 2012). Since asthma 
is regulated by multiple inflammatory cytokines and early studies pointed out its 
possible association with asthma control, we explored the changes in serum 
inflammatory cytokines and other mediators (Akiki et al., 2017). 
The blood analysis was carried out using the Celldyn-3500 counter (Abbot) 
at KAUH’s haematology laboratory. This flow cytometry counter provided 
differential white blood cell counts automatically and was used to measure blood 
eosinophil count. Total serum IgE was measured with the 
radioimmunofluorescent CAP system (Phadia, Sweden) at the clinical 
immunology laboratory of KAUH.  
4.3.1.9 Serum inflammatory mediators 
The serum inflammatory mediators were investigated as an exploratory 
outcome using the Multiplex system of ProcartaPlex Human Inflammation Panel 
20 plex kit (Affymetrix eBioscience, UK) and Luminex® MAGPIX® system reader. 
The kit was pre-set to measure 20 different inflammatory mediators (including 
Cytokines, Chemokines, Growth Factors) in the serum of patients. The explored 
mediators were TNF-α, IFN-α, IFN-γ, IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-
12p70, IL-13, IL-17A/CTLA-8, IP-10, MCP-1, MIP-1α, MIP-1β, P-Selectin, E-
Selectin, GM-CSF, ICAM-1. The kits (Figure 20) were purchased in the UK and 
transferred (temperature controlled) to the study site to analyse inflammatory 
mediators in patients’ serum samples. 
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Figure 20. ProcartaPlex Human Inflammation Panel 20 plex kit was used for 
serum inflammatory mediators’ analysis. 
 
4.3.1.10 Trial procedure 
This study involves two visits. The first visit is for patients’ enrolment and 
assessment of baseline characteristics and outcomes. The second visit is for the 
assessment of intervention outcomes after 4 weeks. 
▪ Visit 1: After identification of eligible patients and signing the consent form, 
the following was conducted: 
1. Recording of patients’ baseline characteristics and outcomes: 
age, body weight, body mass index, pulse, blood pressure, symptoms, 
medications, concomitant therapies, and scores of ACT and PFT. 
2. Blood samples collection: participants were sent to the phlebotomy 
unit at the hospital to collect blood samples for the analysis of 
secondary outcomes.  
3. Randomisation and Allocation: Concealed medications were 
dispensed to participants in a random and blind manner according to 
randomisation table with unique codes recorded on each 
investigational product package. Both the investigator and the patient 
are blinded to treatment or placebo groups. 
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▪ Visit 2 (after 4 weeks): 
The same outcomes measured at baseline were assessed after four 
weeks of treatment to measure the effects of NS oil supplementation. Also, a 
blood sample was collected to detect the change in blood biomarkers. Medication 
compliance was evaluated, and the appearance of any adverse event was 
checked after the first week of treatment as well as at the end of treatment. 
4.3.1.11 Blood and serum collection 
Venous blood samples were collected twice (at the baseline and follow-up 
visit) for the assessment of the secondary outcomes (absolute peripheral blood 
eosinophils count, total serum IgE and multiple serum inflammatory mediators). 
4ml fresh blood was collected in ordinary blood plain tube for differential WBC. 
Also, 6 ml blood was collected in gel tubes (BD vacutainer 367955 tubes with gel, 
BD Plymouth, UK) and centrifuged (by Eppendorf centrifuge 5810 at 3500rpm for 
5min) to yield about 2ml serum which was used for the analysis of total IgE and 
inflammatory mediators. 
4.3.1.12   Statistical analysis 
IBM SPSS v.23 statistical software was used for statistical analysis and 
interpretation of the clinical trial results. The normality of data was assessed 
visually by Q-Q plot. Normally distributed data were represented as mean (SD), 
and independent t-test was used to compare the means of the outcomes between 
two groups. However, non-normal data was represented as median (IQR) and 
Mann–Whitney U test was used to compare the medians of outcomes between 
both groups. Intention-to-treat analysis was used for the primary outcome. 
Multiple regression-substitution was used for imputing primary outcome missing 
data, considering the baseline values. The level of significance for the primary 
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and secondary outcomes was p<0.05. The level of significance for the exploratory 
outcomes was p<0.01. Subgroup group analysis was planned for patients with 
abnormal pulmonary function (FEV1 as % predicted < 80%) and patients with 
high blood eosinophils count (>300 Cells/uL). 
4.3.2 Ethical and logistical considerations   
4.3.2.1 Trial approvals and registrations 
Ethical approval was granted by both the University College London (ref. 
6419/002, Figure 21) and the study site’s ethical committee of King Abdulaziz 
University Hospital (ref. 95-15, Figure 22). Also, the study was approved by the 
national regulatory framework of clinical trials in Saudi Arabia “Saudi FDA” (ref. 
15051902). Also, the Saudi Ministry of Health approved the study (ref. 00637).  
The trial was registered online at www.clinicaltrials.gov in April 2015 (ref. 
NCT02407262, Figure 23), the Saudi Clinical Trials Registry (ref. 15051902, 
Figure 24). Ultimately, the trial became available on the National Health Service 
website (NHS, Figure 25) and the World Health Organisation website (WHO, 
Figure 26) via the international clinical trials registry platform. This was done to 
make the study available to the public and allow publication of the trial results. 




Figure 21. Approval letter of University College London’ ethics. 
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Figure 24. The trial registration within the Saudi Clinical Trials Registry website. 
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Figure 25. The trial registration within the National Health Service website. 
 
 
Figure 26. The trial registration within the World Health Organization website. 
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4.3.2.2  Safety reporting 
According to good clinical practice guidelines, adverse events (AEs) need 
to be reported to ethical committee(s) within relevant time frame (Immediately for 
serious AEs, and 10 days for non-serious AEs) by the primary investigator once 
becoming aware of the event as Related (resulted from the administration of any 
of the research procedures) or Unexpected (not listed in the protocol as an 
expected occurrence). 
4.3.2.3  Data handling 
The clinical data were collected and analysed by the primary investigator 
within six months following the end of the study. Patients’ personal data were 
managed in a confidential way. Sensitive personal data were stored in a secure 
location (locked filing cabinet) and digitally saved at UCL’ secure servers (Data 
Save Haven) with limited access to the primary investigator as well as the PhD 
supervisors for further analysis. Each participant was anonymised by assigning 
an ID number, which used as an identifier in the main dataset. The results of the 
study were written up as part of a PhD thesis and used for publication in peer-
reviewed journals or scientific conferences.   
4.3.2.4  Safety of investigators and patients  
All clinical procedures including patient diagnosis, primary and secondary 
outcome measurements were carried by fully qualified medical doctors (Prof 
Emad Koshak, Prof Siraj Wali and Prof Omer Alamoudi) in collaboration with a 
registered pharmacist (Abdulrahman Koshak) inside the medical clinics and 
laboratories of King Abdulaziz University Hospital.  
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4.3.2.5  Collection of blood samples from patients 
Trained medical staff at a specialised phlebotomy area within King 
Abdulaziz University Hospital were responsible for collecting blood samples from 
patients. 
4.3.2.6  Herbal product adverse effects and interactions 
Overall, adverse effects of NS are rare, although potential adverse effects 
including decreased blood coagulation, decreased blood sugar and decreased 
blood pressure may occur (NaturalMedicines, 2014). Therefore, subjects at high 
risk for occurrence of side effects such as a patient at risk of bleeding were 
excluded from the study. Participants were briefed to look out for any appearance 
of adverse events and advised to stop taking the supplement with immediate 
contact for their physician if any adverse event appeared. 
4.3.2.7  Funding and payments 
There was no direct payment or any kind of reimbursement to participants. 
Participation was voluntary by both the participants and the co-investigators. 
Participants’ interventions, laboratory analysis and diagnostic tests were free of 
charge. All costs occurred were covered by the PhD project bench fees. The trial 
was conducted in a Saudi governmental setting in which healthcare is provided 
free of charge.  
4.3.2.8  Other ethical considerations 
UCL’s Risk Assessment Procedures were followed. The research did not 
include children or vulnerable adults such as individuals with a learning disability 
or cognitive impairment or individuals in a dependent or unequal relationship. 
Participants did not participate in any activities that may be potentially stressful 
or harmful in connection with this research. There was no invasive procedure. 
103 | P a g e 
 
The questionnaire used don’t raise any topics or issues that might be sensitive, 
embarrassing or upsetting for participants. The study was covered by UCL’s 
insurer company. 
4.3.3 Recruitment clinics 
Patients were recruited from the outpatient clinics at King Abdulaziz 
University Hospital (Figure 28). These clinics were managed by five different 
physicians who served as co-investigators in this trial (Table 10). The role of co-
investigators was to identify eligible patients for the trial and refer them to the 
primary investigator. The primary investigator attended all these clinics to 
manage the recruitment of patients and the measurement of outcomes. 
Table 10. The clinics of co-investigators from which patients recruited. 
Co-investigator name Outpatient clinic Time  
Prof Emad Koshak Allergy and Asthma 
Sunday, Tuesday, Thursday 
6pm-9pm 
Prof Siraj Wali Respiratory Wednesday 9am-12pm 






Dr Majdi Qotob 







Figure 27. The study site reception and clinics at King Abdulaziz University Hospital. 
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4.4 Results and discussion 
4.4.1 Patients 
Between Jun 1, 2015 and Dec 30, 2015, 140 patients with asthma were 
assessed for eligibility. Of them, 80 patients were enrolled and randomised (1:1) 
into two groups, the treatment and placebo groups. In each group, 10 patients 
did not complete the study. Reasons for drop-out were mainly due to non-medical 
reasons such as loss of interest and inability to attend. Four patients had medical 
related reasons such as adverse events and asthma exacerbation. At the 
beginning of the study, a large proportion of patients dropped out since they lived 
far away from the study site. Therefore, it was decided to exclude patients who 
are living outside the city. Also, patients were encouraged to come for follow-up 
by providing them with an extra check-up by the medical team. The recruitment 
flow chart and details of drop-out reasons are provided in Figure 28. The baseline 
demographics of the recruited patients are presented in Table 10. All participating 
patients were previously diagnosed with asthma and were on regular asthma 
medications that were adjusted and optimised according to GINA guidelines for 
standard asthma management (Global Initiative for Asthma, 2017). These 
medications were inhaled short-acting beta agonists (salbutamol), inhaled long-
acting beta agonists (salmeterol or formoterol), inhaled corticosteroids 
(budesonide or fluticasone), oral anti-leukotrienes (montelukast). 
  








40 included in intention-to-
treat analysis   
(Primary outcome data 
imputed for 10 patients) 
 
40 included in intention-to-
treat analysis  
(Primary outcome data 
imputed for 10 patients) 
 
Assessed for eligibility (n=140) 
Analysis 
Excluded (n= 60) 
22 didn’t meet inclusion criteria 
8   declined to participate 
30 other reasons (living in a far   
distance location, stated 
inability to follow-up, had a 
scheduled medical operation)  
Lost to follow-up (n=10) 
1 unable to attend (out of city, 
difficult transportation) 
3 not responding 
3 lost interest 
1 had exams in school 
1 had oral corticosteroid 
therapy 
1 side effect insomnia 
 
Allocated to placebo (n= 40) 
Lost to follow-up (n=10) 
1 had operation 
1 had asthma exacerbation 
2 unable to attend (out of city, 
difficult transportation) 
3 lost interest 
1 not responding 
2 side effects; insomnia, 
headache, nausea      
 




 Figure 28. Flow diagram of patient’s enrolment. 
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Table 11. Baseline demographics of subjects. 
Variable Treatment (n=40) Placebo (n=40) 
Age 39 (13) 42 (15) 
Men 15 (38%) 18 (45%) 
Women 25 (62%) 22 (55%) 
BMI 28 (5) 30 (8) 
Predicted FEV1% 74 (17) 72 (16) 
Total ACT 16.0 (3.9) 16.5 (3.6) 
Blood eosinophil 
count, Cells/uL 
350 (187 – 711) 300 (135 – 415) 






12%, Montelukast 10mg  
14%, Symbicort 160/4.5mcg 
2%, Theophylline 250mg 
10%, Montelukast 10mg  
12%, Symbicort 160/4.5mcg 
4%, Theophylline 250mg 
Values represented as mean (SD), n (%), or median (IQR). 
4.4.2 Compliance with medications 
Medication compliance was assessed by counting the remaining capsules 
and was referred as “good” if the patient adhered to 80-100% of study treatment 
regimen. Treatment adherence was assessed by direct questioning of patients 
during the treatment period and at the follow-up visit. Ultimately, 95% of patients 
fulfilled this criterion and had a good compliance. Few patients (5%) had poor 
compliance as they adhered to less than 80% of the treatment regimen. 
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4.5 Efficacy 
4.5.1 Asthma Control Test  
Inspection of Q-Q plots revealed that Asthma Control Test (ACT) scores 
were close to normally distributed for both groups. Therefore, independent t-test 
was used for significance testing between means with a 95% confidence interval 
(CI).  
The baseline scores of the mean total ACT were not significantly different 
between the treatment (n=40) and placebo group (n=40). All randomised 80 
patients were statistically analysed for the primary outcome by using the 
intention-to-treat method of analysis. This method was used to include the 
withdrawn patients in the analysis by imputing the missing data of 10 patients 
using SPSS statistical software. 
As a primary outcome, the mean total ACT score in the treatment group 
was significantly higher than the placebo group at the end of the study, as shown 
in Table 12.  
In addition, the five individual questions of ACT (ACT sub-scores) were 
analysed as secondary outcomes. Significant improvement was found in the 1st 
and 5th questions of the ACT which reflects a significant improvement in daily 
functioning and overall self-assessment of asthma control. However, there was a 
non-significant improvement in general asthma symptoms, the frequency of 
shortness of breath and use of rescue medications (2nd, 3rd and 4th questions of 
the ACT) as shown in Table 13. 
Our findings in asthma symptom control, measured by the ACT, were 
consistent with symptoms improvement in previous clinical studies of NS in 
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asthmatic patients. NS oil enhanced scores of subjective improvement in clinical 
symptoms of allergic conditions including asthma (Kalus et al., 2003). An 
aqueous extract of NS significantly improved the severity of asthma symptoms 
(Boskabady et al., 2007). The administration of powdered NS among asthmatic 
children with immunotherapy significantly increased ACT scores (Sugiono et al., 
2013).  
Table 12. Scores of total Asthma Control Test. 










Total ACT 16.0 (3.9) 16.6 (3.6) 0.44 21.1 (3.1) 19.6 (3.9) 0.04 
Values represented as mean (SD) 
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Table 13. Sub-scores of Asthma Control Test. 











functioning)   
3.4 (0.9) 3.3 (1.1) 0.62 4.4 (0.6) 3.8 (0.9) 0.01 
Q2 (frequency 
of shortness of 
breath) 
3.1 (1.0) 3.4 (1.0) 0.22 4.2 (0.7) 3.9 (0.9) 0.28 
Q3 (night 
symptoms) 
3.3 (1.3) 3.6 (1.2) 0.27 4.4 (0.7) 4.0 (1.1) 0.14 
Q4 (use of 
rescue 
medications) 





2.7 (0.7) 2.7 (0.9) 1.00 4.1 (0.6) 3.5 (0.9) 0.01 
Values represented as mean (SD).  Q1-Q5 are the individual questions of 
ACT. *Q1=In the past 4 weeks, how much of the time did your asthma keep 
you from getting as much done at work, school or at home?, Q2=During the 
past 4 weeks, how often have you had shortness of breath?, Q3= During the 
past 4 weeks, how often did your asthma symptoms (wheezing, coughing, 
shortness of breath, chest tightness or pain) wake you up at night or earlier 
than usual in the morning?, Q4= During the past 4 weeks, how often have 
you used your rescue inhaler or nebulizer medication?, Q5= . How would you 
rate your asthma control during the past 4 weeks?. 
Values represented as mean (SD). 
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4.5.2 Pulmonary function test 
Inspection of Q-Q Plots revealed that pulmonary function test scores were 
not close to a normal distribution for both groups. Therefore, Mann-Whitney U 
Test was used for significance testing between medians with a 95% confidence 
interval (CI). 
At the end of the study, there was a trend for an improvement in the 
predicted FEV1% and PEF% in the treatment group (n=25) versus the placebo 
group (n=24). However, the changes in pulmonary function were not statistically 
significant (Table 14). Eleven patients in both groups (5 in the treatment group 
and 6 in the placebo group), were not able to successfully perform the pulmonary 
function test due to breathing difficulty. 
Table 14. Changes in pulmonary function test. 
Parameter 
Change in placebo 
group (n=24) 
Change in treatment 
group (n=25) 
p 
FEV1 as % predicted 1.00 (-2.00 to 5.00) 4.00 (-1.25 to 8.75) 0.170 
PEF as % predicted 2.00 (0.00 to 14.50) 6.50 (0.25 to 22.75) 0.279 
FEF25-75% as 
% predicted 
3.00 (-6.50 to 16.50) 2.50 (-7.75 to 18.75) 0.992 
Values represented as median (IQR).  FEV1: Forced expiratory volume in 1 
second. PEF: Peak expiratory flow. FEF 25-75%: Forced expiratory flow 
between 25-75%. 
 
Alternatively, subgroup analysis of patients with below normal predicted 
FEV1% (<80%) at baseline had a significant improvement in the treatment 
subgroup (n= 14) vs placebo subgroup (n= 15) by median= 8% (IQR= 3 to 13%) 
vs median= 1% (IQR= -2 to 5%) (p= 0.018), respectively. Their mean total ACT 
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scores were 21.93 (SD= 1.9) for the treatment group vs 19.07 (SD= 3.3) for the 
placebo group with p=0.01. Also, their median change in PEF (% predicted) 
scores were 6.5 (IQR= 1.0 to 14.5) for the treatment vs 2.0 (IQR= 0.0 to 10.0) for 
the placebo with p=0.25. 
The baseline characteristics of the subgroups are shown in Table 15. 
Table 15. Baseline characteristics of subgroups with below normal predicted 
FEV1% (<80%) 
Variable Treatment (n=14) Placebo (n=15) 
Age 41 (8.8) 46 (15) 
Men 5 (36%) 4 (27%) 
Women 9 (64%) 11 (73%) 
BMI 28 (5) 30 (5) 
Predicted FEV1% 63 (10) 62 (11) 
Total ACT 17.6 (3.5) 16.7 (3.2) 
Blood eosinophil count, Cells/uL 448 (163 to 820) 271 (130 to 350) 
Total IgE, IU/Ml 151 (53 to 369) 305 (58 to 718) 
Values represented as mean (SD), n (%), or median (IQR). 
 
In a previous clinical study, an aqueous extract of NS significantly 
improved pulmonary function parameters in the treatment vs. placebo group only 
after 3 months treatment but all patients in this study had an abnormal pulmonary 
function at baseline (Boskabady et al., 2007). Also, an aqueous extract of NS 
showed a significant improvement in pulmonary function parameters in short time 
effect (30 min until 150min), but the results were not compared to placebo, and 
all patients (15 asthmatics) had an abnormal pulmonary function at baseline 
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(Boskabady, Mohsenpoor and Takaloo, 2010).  In a non-RCT open-label clinical 
study, NS seeds combined with bee honey improved pulmonary function, but this 
study was not placebo controlled and included only 5 asthmatics (Al Ameen et 
al., 2011). 
4.5.3 Blood biomarkers 
4.5.3.1 Absolute blood eosinophil count  
Inspection of Q-Q Plots revealed that the absolute blood eosinophil count 
scores were not close to a normal distribution for both groups. Therefore, Mann-
Whitney U Test was used for significance testing between medians with a 95% 
confidence interval (CI). 
There was a significant reduction in the absolute blood eosinophil count in 
the treatment group (n=30) compared to the placebo group (n=30) by a median 
of -50 (IQR= -1 to -155) versus a median of 15 (IQR= -60 to 87) cells/uL (p= 
0.013) as shown in Figure 29. 
Figure 29. Change in absolute blood eosinophil count level from baseline. 
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The following is a subgroup analysis of patients who had high absolute 
blood eosinophil count (Eosinophilia) at baseline (>350 cells/uL). Eosinophilia  
was found in 16 patients (%) in the treatment group and 15 patients in the placebo 
group (%). The analysis of this subgroup showed a median change for the blood 
eosinophil count by -145 (IQR= -42 to -422) cells/uL for the treatment (n=16) 
versus 20 (IQR= -130 to 140) cells/uL for the placebo (n=15) with p=0.03. Also, 
their total ACT scores after treatment were 21.5 (SD=2.3) for the treatment group 
vs 19.5 (SD=4.0) for the placebo group with p=0.1. In addition, the change in 
median FEV1 (% Predicted) were 6.5 (IQR= 3.2 to 12.2) for the treatment group 
vs 2.0 (IQR= -2.0 to 4.0) for the placebo group with p=0.009. 
To our knowledge, this is the largest RDBPCT study discovered a 
remarkable reduction of peripheral blood eosinophil count by NS oil in asthmatic 
patients. In a previous clinical trial, there was a non-significant decrease of 
blood eosinophils within NS oil group. However, this study included 3 asthmatic 
patients only and did not statistically compare the results of blood eosinophil 
count between groups (Kalus et al., 2003). 
4.5.3.2  Total serum immunoglobulin E 
Inspection of Q-Q plots revealed that total serum immunoglobulin E (IgE) 
scores were not close to a normal distribution for both groups. Therefore, Mann-
Whitney U Test was used for significance testing between medians with a 95% 
confidence interval (CI).  
There was no significant change found on the total serum IgE level 
between both groups (n=30 each) as shown in Figure 30. This was consistent 
with findings of Kalus et al. (2003) who reported a non-significant IgE changes 
within NS oil group. However, the study of Kalus et al. (2003) included only 3 
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asthmatic patients and did not statistically compare the total serum IgE changes 
between groups. In another clinical trial, there was a significant reduction of total 
serum IgE in the group of NS, but this study was conducted in children, was not 
double-blinded placebo-controlled, and NS was combined with probiotics and 
immunotherapy (Sugiono et al., 2013). 
Figure 30. Change in total serum immunoglobulin E level from baseline. 
 
4.5.3.3  Serum inflammatory mediators 
Inspection of Q-Q Plots revealed that serum inflammatory mediators 
scores were not close to a normal distribution for both groups. Therefore, Mann-
Whitney U Test was used for significance testing between medians with a 95% 
confidence interval (CI). 
In the treatment group (n=26), there was a trend for upregulation of the 
serum inflammatory mediators IL-10, IP-10, IFNγ and IL-12p70 from baseline 
scores in comparison to placebo (n=27) (Figures 31-34). However, no significant 
changes were found in the other inflammatory mediators between groups (Table 
16). Therefore, NS may have a role in upregulating the serum levels of Th1 cell 
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promoting factors (IFNγ, IL-12p70), Th1 secreted cytokines (IL-10, IFNγ) and 
IFNγ-induced protein (IP-10) when compared to placebo. This trend of Th1 
cytokines domination may be useful to counteract the elevation of Th2 cytokines 
found in asthmatic patients and hopefully restore Th1/Th2 balance (Ray and 
Cohn, 2000). In a RSBPCT, powdered NS increased serum IFNγ in patients with 
asthma (Salem et al., 2017). In an RDBPCT, NS oil increased serum level of IL-
10 in patients with rheumatoid arthritis (Hadi et al., 2016). 
Scientific studies showed that modifying cytokine profile of Th2 cells by 
induction of Th1 responses may benefit Th2-related diseases such as asthma 
(Teixeira et al., 2005). IFNγ showed a positive role in allergic-related diseases 
and reduced level of IFNγ was associated with severe asthma (Teixeira et al., 
2005). IFNγ showed a reduction of blood eosinophil count in patients with severe 
steroid-dependent asthma (Barnes et al., 2009). The anti-inflammatory cytokine 
(IL-10) may have a beneficial role for the control of asthma and allergy (Urry, 
Xystrakis and Hawrylowicz, 2006). IL-12 cytokine may have a potential role in 
asthma therapy, and several in-vivo studies showed that IL-12 could inhibit 
allergic airway inflammation in asthma (Leonard and Sur, 2003). Inhalation of IL-
12 appeared to be inhibiting allergic inflammation in murine models (Leonard and 
Sur, 2003). IL-12 might reduce eosinophilic inflammation as administration of 
recombinant human IL-12 to asthmatic patients resulted in a decrease of blood 
and sputum eosinophils count and improved airway hyperresponsiveness 
(Barnes et al., 2009). 
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Figure 31. Change in serum interleukin-10 level from baseline. 
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Table 16. Changes in serum inflammatory mediators. 
Mediator Median changes from baseline 
 Placebo (pg/mL) Treatment (pg/mL) p 
IL-1β -0.2 (-0.8 – 0.4) -0.3 (-0.5 – 0.1) 0.972 
IL-1α -6 (-17.8 – 6.6) -1.8 (-8.5 – 8.7) 0.207 
IL-4 -6.2 (-28.2 – 2.4) 0.8 (-24.8 – 23.6) 0.113 
IL-6 -7 (-18.7 – 6) -3 (-7.3 – 4.6) 0.319 
IL-8 -2.4 (-3.9 – 0.4) 0.1 (-4 – 1.7) 0.286 
IL-10 -0.3 (-0.9 – 0) 0 (-0.2 – 0.3) 0.019 
IP-10 -24.3 (-34 – 0) -4.1 (-17.4 – 12.8) 0.046 
IL-12p70 -14.4 (-32 – 6.5) -1.6 (-20.8 – 10.8) 0.048 
IL-13 -1.4 (-2 – 0.2) -0.3 (-1.9 – 2.5) 0.140 
IL-17A -1.2 (-3.2 – 0) -1.2 (-2.4 – 0.8) 0.499 
INF-α -0.5 (-2.1 – 0.4) -0.1 (-1.2 – 0.9) 0.220 
INF-γ -18.7 (-51.8 – 1.8) 2.8 (-17 – 15.9) 0.039 
TNF-α -24.8 (-103.8 – 24.5) -14 (-50 – 46.1) 0.188 
sICAM-1 -30820 (-192561 – 81074) 5104 (-24230 – 68982) 0.182 
MIP-1α -9.6 (-43.3 – 10.9) -1.1(-14.3 – 11.3) 0.423 
MIP-1β -55.1 (-132.6 – 133.7) -14.6 (-84.6 – 63.8) 0.656 
MCP-1 -24.5 (-116.2 – 90.6) 5.7 (-94.9 – 86.9) 0.477 
P-Selectin -17758 (-93719 – 17533) 1345 (-72982 – 120603) 0.466 
E-Selectin -5426 (-18032 – -1794) -634 (-8206 – 2202) 0.024 
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4.6 Safety and tolerability  
Three patients (two from the treatment group and one from the placebo 
group) reported three adverse events including; stomach upset, headache, and 
insomnia. These adverse events were mild and self-limited (did not require any 
treatment or hospitalisation). The study treatment is considered to be tolerable 
as only two patients (one from the treatment group and one from the placebo 
group) discontinued the study due to adverse events. 
4.7 Study limitations 
This clinical study had several limitations. The duration of the intervention 
is relatively short (four weeks only), and the sample was comparatively small. 
This was due to time limitation of the PhD study. A relatively high drop-out rate 
which resulted from reasons not related to study design or medication, but rather 
due to unexpected reasons not considered initially including the geographical 
mobility of some of the study participants. Also, the lack of incentives for 
participants (due to limited funding) along with the socioeconomic status of some 
the participants played a role in patient retention rate. The time of using 
bronchodilator medication before measuring pulmonary function was not 
considered and this may affect the final results of pulmonary function parameters.  
The choice of outcomes was dependent on its applicability and availability at the 
study site. Additional asthma outcomes and biomarkers such as FeNO, Sputum 
eosinophils, allergen-specific IgE and urinary LTE4 may be considered in the 
future studies (Szefler et al., 2012). 
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4.8 Conclusion  
In this study, four weeks of add-on (complementary) treatment with NS oil 
significantly improved asthma symptom control over placebo and showed a trend 
toward pulmonary function improvement with an acceptable safety and tolerability 
profile in adult asthmatic patients. Remarkably, NS oil showed a reduction of the 
biomarker blood eosinophilia. In addition, the changes in the serum cytokines 
levels indicated a potential immunomodulatory effect of NS toward the 
upregulation of Th1 specific cytokines which may result in balancing the impaired 
Th1/Th2 cytokines balance in the context of asthma. However, significant 
changes in total serum IgE did not occur.  
These findings provided an evidence base for the probable benefits of NS 
oil supplementation in the clinical management of asthma. To our knowledge, this 
is the largest sample size RDBPCT of using NS oil in patients with asthma and 
compared the effect of NS oil on blood eosinophils between the two groups 
(treatment versus placebo). In the future, studies should follow patients for a 
longer period with a larger group of patients and consider further outcomes in a 
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5 Chapter 5 General discussion and conclusion 
5.1 General discussion 
In the era of evidence-based medicine, well-designed clinical studies are 
essential to evaluate the safety and efficacy of herbal medicines for the treatment 
of human diseases. This project addressed some vital needs for conducting 
clinical trials using herbal medicines. Many clinical trials using herbal medicines 
often have drawbacks that limit the scientific rationale for the clinical use of herbal 
medicines. A key problem of clinical research with herbal medicines is the quality 
and the lack of a clear characterisation of the studied material. Specifically, the 
variability of herbal preparations used may lead to a discrepancy in the results 
and conflicting conclusions about the safety and efficacy of herbal medicines. 
This project addressed this problem by combining a phytochemical and 
pharmacological characterisation with a clinical trial of a herbal medicine. In 
addition, this project has overcome the financial challenge for clinical trials 
especially using herbal medicines by conducting the trial in a local government 
university hospital in which healthcare is provided free of charge. 
The general approach of this study comprised of three phases. The first 
phase was to assess and identify the weaknesses in the evidence for the clinical 
use of NS in asthma (Chapter 1). The second phase was the pre-clinical 
characterisation (including chemical and pharmacological) of NS preparations 
and identifying the most suitable preparations for a clinical trial (Chapter 2 and 
3). The last phase was the designing and conducting a randomised double-blind 
placebo-controlled clinical trial on the supplementary use of NS in patients with 
asthma. 
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Our project was focused on asthma disease as one of the leading chronic 
respiratory illnesses. Due to the limitations of conventional asthma medications, 
patients with asthma may tend to use herbal medicines as one of the modalities 
of unconventional treatment approaches. Nigella sativa (NS) is one of the most 
popular medicinal plants among different communities, especially in the Arab and 
Islamic countries. The religious significance and several medicinal benefits 
associated with NS made it a culturally and commercially valuable plant. In Saudi 
Arabia, NS is one of the most frequently used non-standard treatments among 
asthmatic. However, the evidence for the use of NS in asthma is not well 
established. Therefore, this project came to establish a scientific basis for the 
clinical use of NS in patients with asthma via addressing the current limitations of 
the scientific evidence and overcoming these limitations with unique mixed 
methods approach of combined chemical, pre-clinical pharmacological and 
clinical investigations. 
The literature review provided an important update on the evidence of the 
use of NS in asthma disease (Chapter 1). Based on the literature review, it 
became apparent that NS had empirical evidence for its anti-asthmatic effect in 
traditional medical textbooks as well as experimental pre-clinical and clinical 
studies. However, these experimental studies had limitations such as quality of 
study design, sample size, investigated outcomes, and most importantly the 
variability of the investigational NS preparation and its chemical characterisation 
among different studies. Hence, the evidence base for the clinical use of NS in 
asthma is limited and unclear. A specific approach for the chemical and 
pharmacological characterisation of an NS preparation was necessary to find a 
suitable high-quality active preparation of NS that can be used in a clinical trial. 
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In the second chapter of phytochemical characterisation, ten NS 
preparations (extracts 1-10) were obtained via either a specific method of 
extraction using different percentages of combined water/ethanol extraction 
solvents (extracts 1-6) or inclusion of ready-made commercial NS products 
(extracts 7-10). All NS preparations were chemically characterised by 
quantification of the main active compound TQ. This experiment was important 
to provide an overview of the variability in the chemical composition and allowed 
to assess the level of the key active compound TQ among different NS 
preparations. The level of TQ was highest in the oily extracts, especially the 
supercritical fluid extract (no. 7) and the commercial oil capsules by Marnys, 
Spain (no. 10). However, preparations extracted with water or combination of 
water/ethanol did not contain a substantial amount of TQ due to the poor stability 
and solubility of TQ in aqueous solutions. This variability in the chemical 
composition was due to the method of preparations, which is a vital element that 
can affect the pharmacological activity of NS. 
In the third chapter, several in vitro models of 
inflammation/immunomodulation were used for the pharmacological 
characterisation of the NS preparations. The effect of NS preparations on the 
inhibition of inflammatory mediators (IL-6, IL-2, PGE2) and inflammatory 
signalling pathway (p38 MAPK) was investigated in human T-lymphocyte cells 
and monocytes as well as A549 lung epithelial cell line. The results of this 
experiments revealed that thymoquinone-rich extracts (especially extract no. 7 
and 10) appeared to be the most potent active extracts in the context of anti-
inflammatory/immunomodulatory activities. The variability of the in vitro activity of 
NS preparations was most probably due to the differences in the chemical 
composition of NS preparations. Our results provided a direct pre-clinical 
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evidence that NS inhibited the release of some cytokines with inflammatory 
properties which are found to be upregulated patients with asthma, and relatively 
NS had corticosteroid like effect in abolishing this upregulation to induce 
remission of asthmatic symptoms. Interestingly, NS also induced the release of 
PGE2 cytokine which thought to have a bronchodilatory effect in bronchial 
epithelium. This experiment was a very useful tool that enabled us to identify the 
most active NS preparations that can be selected for a clinical trial. In order to 
achieve the effective concentration (100mcg/ml) in vivo, it is necessary to know 
the bioavailability of TQ. Due to the lack of knowledge on the clinical 
bioavailability of TQ, it is difficult to translate our in vitro effective dose into an oral 
human dose. 
In the fourth chapter, the design of the clinical trial was developed based on 
the existing literature for outcomes selection taking into consideration the co-
investigators recommendation. In the Saudi Arabian context, extract 10 was the 
most logistically suitable for a clinical trial because it is licensed with Saudi Food 
and Drug Authority. Our RDBPCT showed that the NS oil group had a statistical 
significant improvement in the total ACT score.  Although the total ACT score 
increased significantly more in the treatment group than in the control group, the 
difference between the groups did not reach the clinically important change of 3 
points. The improvement of total ACT score in the placebo group is most probably 
due to changing the conventional medications of patients. This effect was 
accompanied by a marked normalisation of blood eosinophilia, which is 
considered a biomarker of asthma. Also, a trend of pulmonary function 
improvement (predicted FEV1%) was seen in the NS oil group. However, there 
were no significant changes in serum total IgE. These insignificant outcomes may 
reach statistical significance by administration of a higher dose of NS for a longer 
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period with larger sample size. Interestingly, this study was the first clinical trial 
explored the effect of NS on a wide range of serum inflammatory cytokines in 
asthmatics, which early studies suggested that some of these serum cytokines 
might be associated with asthma control. The serum cytokines IL-10, IFNγ, IP-10 
and IL-12p70 had a trend of increase in the NS group compared to placebo but 
not significant. This might point out that NS may affect the Th1/Th2 cytokines 
balance by probable upregulation of Th1 cytokines which can consequently 
counteract the Th2 elevation in asthma. The result of this study is consistent with 
previous clinical studies in asthma symptom control. Interestingly, this study 
discovered a potential effect of NS on improving blood eosinophilia so that NS 
may be used as an anti-eosinophilic agent in several diseases. 
Novel therapeutic approaches for asthma management are targeting 
disease-specific phenotypes. Severe eosinophilic (allergic) asthma is one of the 
difficult asthma groups that may have limited response to available treatments 
(Pavord et al., 2017). Currently, late-onset eosinophilic asthma is one of the 
common asthma phenotypes associated with very poor quality of life and frequent 
exacerbations (Groot, Brinke and Bel, 2015). Therefore, NS may be a potential 
controller or add-on treatment option for the allergic phenotype of asthma which 
is associated with eosinophilic airway inflammation if patients had limited 
response to inhaled corticosteroids.  
 The findings of this study are important because it provided a higher quality 
of clinical evidence for the benefits of the complementary (add-on) use of NS on 
asthma symptoms and blood eosinophilia.  
In the GINA guided stepwise approach for asthma management, the 
introduction of NS is potentially suggested from step 2 as a controller medication 
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to reduce airway inflammation or add-on option for patients with severe asthma. 
Step 1 is usually mild intermittent asthma that can be managed by as-needed 
short-acting beta2-agonist (Global Initiative for Asthma, 2017).  
If the efficacy of NS is well-established as a complementary treatment 
option for patients with asthma, it may offer cost-effectiveness benefits through 
reducing the use of high-cost asthma medications or preventing its side-effects. 
For example, in Saudi Arabia, the cost of commonly used controller medications 
such as Symbicort 80 mcg/4.5 mcg turbohaler (budesonide, formoterol) is 129.55 
SAR (approx. £26) for an average one month supply. Another example is 
Singulair 5 mg (montelukast) costs 123.6 (approx. £24) for an average one month 
supply. On the other hand, the used NS capsules in our trial (Marnys Cuminmar 
500 mg) costs 50 SAR (approx. £10) for an average of one to two months’ supply. 
This research project had several limitations. First, the targets used in the 
in vitro screening of the NS preparations were considered to be general 
inflammatory targets that have some relationship with asthma. This was due to 
the limitations in funding and the capabilities of the laboratory in which this 
screening was conducted. It would be more appropriate to investigate classical 
targets in asthma disease such as to compare the effect of NS preparations on 
the release of Th2 cytokines IL-4, IL-5, and IL-13 in in vitro models. 
Second, the choice of the investigational NS product was dependent on 
two major factors which are high in vitro activity and logistical suitability within the 
clinical trial site. If we base our choice on the most potent preparation, the 
supercritical fluid preparation (extract 7) would be the first choice. However, it 
would be more complex and time-consuming to implement extract 7 in the clinical 
trial because it was not available in capsules form, not registered with any 
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pharmaceutical regulatory framework and had no safety data. Therefore, the 
commercial oil product by Marnys, Spain (extract 10) which a relative high in vitro 
activity and being registered within the Saudi regulatory framework of herbal 
medicinal products (SFDA) was chosen for the clinical trial. This facilitated getting 
the logistical approval to conduct the clinical trial in Saudi Arabia, and it was more 
acceptable by the collaborating clinical team as well as the patients to use a 
product that already been in the Saudi pharmaceutical market.  
Third, the dose of NS oil used in this trial was determined based on the 
manufacturer recommendation (2-3 capsules of 500mg daily) as well as previous 
clinical trials. Thus, a dose-escalating clinical trial could be a helpful step to find 
an optimal dose prior to the clinical efficacy trial. 
Fourth, the trial was relatively short in duration, small in sample size and 
the choice of outcomes was limited to the applicability and logistical factors 
mainly. These limitations stem from the fact that the clinical trial was conducted 
mainly by a single researcher (the PhD student) who was responsible for running 
the trial and data collection at a single centre. Also, there were some logistical 
reasons that limited the number of participants such as lack of incentives for the 
participants and difficult transportation for some participants (can’t afford 
transportation cost or living in far areas). Thus, providing patients with incentives, 
compensation for transportation and extra medical care might be useful to 
minimise patient withdrawal. After few patients dropped out due to difficult 
transportation, only patients living the same city or who assured they can come 
for follow-up were recruited. Given the timeframe of a PhD study and the difficulty 
in convincing the patient to come for a second or third follow-up, it was difficult to 
have longer duration trial and patients were given four weeks only. The asthma 
biomarkers choice was based on its feasibility and recommendation by 
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collaborators. For example, sputum eosinophils and urinary leukotrienes are 
which were not used in this trial due to the complexity of implementation. 
In the future, a well-designed clinical trial characterised by larger sample 
size (more than 80 patients), longer duration (more than 4 weeks), including 
multiple trial sites and additional outcomes (such as fractional exhaled nitric 
oxide, sputum eosinophils,  serum allergen-specific IgE and urinary Leukotriene 
E4 (Szefler et al., 2012) is recommended to establish a stronger evidence for the 
clinical use of NS oil in patients with asthma. This may result in better outcomes 
especially in pulmonary function and serum total IgE. Also, elucidating the 
mechanism of action would be an interesting topic of exploration in future studies. 
Also, there is a high demand to establish the clinical bioavailability and 
pharmacokinetic parameters of NS especially for the main active compounds 
such as thymoquinone. Thus, the next suggested step is to conduct a clinical 
pharmacokinetic and dose-finding study to optimise the dosage of oral NS oil 
followed by a longer-term trial to investigate other outcomes such as frequency 
of exacerbations and asthma medications. In the future, this trial may be 
combined with other randomised clinical trials of NS in asthma into a meta-
analysis study to provide a higher level of evidence for the use of NS in patients 
with asthma.  
5.2 General conclusion 
Asthma is a leading chronic disease characterised by suboptimal control 
regardless of the availability of conventional medications. This project evaluated 
the use of the herbal medicine Nigella sativa oil in asthma as an add-on 
treatment. NS is considered a traditional remedy for asthma, but the scientific 
evidence for the clinical use of NS in patients with asthma is not well established 
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and had several limitations which encouraged us to conduct a properly designed 
clinical trial using a chemically and pharmacologically characterised NS 
preparation. Clearly, there is a link between the phytochemistry and 
pharmacological activity of herbal preparations. Combining pre-clinical 
characterisation (both chemical and pharmacological) with a well-designed 
clinical trial is a very important step for investigating the safety and efficacy of 
herbal medicines. We found a variability in the chemical composition as well as 
the pharmacological activity of different NS preparations. The oily preparations 
especially extract 7 (a supercritical fluid extract) and extract 10 (a commercial 
product by Marnys, Spain) contained the highest concentrations of the key active 
volatile oil compound TQ. Both extracts showed the best anti-inflammatory / 
immunomodulatory activity in in vitro inflammatory models. Our randomised, 
double-blind, placebo-controlled phase-II clinical trial of NS, using a commercial 
herbal product registered in Saudi Arabia, provided a higher level of evidence for 
the clinical improvement of asthma symptoms control and blood eosinophilia by 
NS in patients with asthma. In the future, a multicentre clinical trial with longer 
duration, larger sample size, and additional biomarkers is required to establish a 
stronger level of evidence for the clinical use of NS in patients with asthma. In the 
end, this project provided an example of a scientific methodology for the 
assessment of the clinical efficacy of a herbal medicine considering the specific 
needs of clinical research using a herbal derived material.   
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6 Publications 
6.1 Original papers 
- Koshak, A., Wei, L., Koshak, E., Wali, S., Alamoudi, O., Demerdash, A., 
Qutub, M., Pushparaj, P. N. and Heinrich, M. (2017) ‘Nigella sativa 
Supplementation Improves Asthma Control and Biomarkers: A Randomized, 
Double-Blind, Placebo-Controlled Trial’, Phytotherapy Research. doi: 
10.1002/ptr.5761. 
 
- Koshak, A., Koshak, E. and Heinrich, M. (2017) ‘Medicinal benefits of Nigella 
sativa in bronchial asthma: A literature review’, Saudi Pharmaceutical 
Journal. doi: 10.1016/j.jsps.2017.07.002. 
 
6.2 Conference poster presentations 
- The 9th Joint Natural Products Conference 2016, Copenhagen, Denmark 
Koshak, A., Wei, L., Koshak, E., Wali, S., Alamoudi, O., Demerdash, A., Qutub, 
M., Pushparaj, P. and Heinrich, M. (2016) ‘Potential benefits of Nigella sativa oil 
supplementation on asthma inflammation: a randomised, double-blind, placebo-
controlled, exploratory phase-II clinical trial’, Planta Medica. 81(S 01), pp. S1–
S381. doi: 10.1055/s-0036-1596928. 
 
- The UCL Institute of Immunity and Transplantation Annual Symposium 2016, 
London, UK 
Koshak, A., Wei, L., Koshak, E., Wali, S., Alamoudi, O., Demerdash, A., Qutub, 
M., Pushparaj, P. and Heinrich, M. (2016) ‘Immunomodulatory effects of Nigella 
sativa oil supplementation in patients with asthma: an RCT’, in The UCL Institute 
of Immunity and Transplantation Annual Immunology Symposium with Pears 
Lecture. Royal Free Campus, University College London, London, UK. 
 
- European Academy of Allergy and Clinical Immunology Congress 2015, 
Barcelona, Spain 
Koshak, A., Fiebich, B., Koshak, E. and Heinrich, M. (2015) ‘Comparative anti-
inflammatory / immunomodulatory effect of different extracts of the medicinal 
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plant Nigella sativa’, in European Academy of Allergy and Clinical Immunology 




(Accessed: 6 March 2017). 
 
6.3 Conference oral presentations 
- World Integrative Medicine Congress 2017, Berlin, Germany 
- European Respiratory Society International Congress 2016, London, UK 
Koshak, A., Wei, L., Koshak, E., Wali, S., Alamoudi, O., Demerdash, A., Qutub, 
M., Pushparaj, P. and Heinrich, M. (2016) ‘LATE-BREAKING ABSTRACT: The 
benefits of Nigella sativa oil supplementation on asthma inflammation: A 
randomised, double-blind, placebo-controlled, phase II trial’, European 
Respiratory Journal. European Respiratory Society, 48(suppl 60), p. OA4830. 
doi: 10.1183/13993003.congress-2016.OA4830. 
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8 Appendix  
Figure 35. HPLC chromatogram of Nigella sativa extract 1. 
 
Figure 36. HPLC chromatogram of Nigella sativa extract 2. 
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Figure 38. HPLC chromatogram of Nigella sativa extract 4. 
 
Figure 39. HPLC chromatogram of Nigella sativa extract 5. 
 
Figure 40. HPLC chromatogram of Nigella sativa extract 7. 
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